Introduction {#s1}
============

The proper folding of proteins is essential to cellular homeostasis, and an extensive collection of protein quality control (PQC) pathways, known as the proteostasis network, has evolved to protect nascent and metastable proteins from misfolding and to reactivate or remove proteins that have already misfolded ([@bib65]; [@bib96]). The PQC network is tailored to buffer protein folding in a distinct homeostatic niche but can adapt when these buffering thresholds are exceeded by elevating the expression of PQC factors, including proteases and molecular chaperones, to clear accumulating misfolded proteins ([@bib55]; [@bib65]). In cases such as thermal stress, these corrections are sufficient to restore balance, but in others such as aging, misfolded proteins assemble into ordered amyloid aggregates, which persist and dramatically alter cellular physiology by inducing disease ([@bib88]; [@bib90]; [@bib82]; [@bib39]). This proteostasis collapse has been linked to the unique ability of amyloids to incorporate and conformationally convert like protein to the misfolded state and to their high thermodynamic stability ([@bib8]; [@bib32]). Together, these properties are thought to enhance the production and restrict the resolution of the misfolded protein to the point that the buffering capacity and adaptability of the proteostasis network is chronically exceeded.

Despite this natural upper boundary on proteostasis capacity, the heterologous overexpression of molecular chaperones in *Caenorhabditis elegans*, mice, *Drosophila*, yeast, and tissue culture-cell models of amyloidoses reduces proteotoxicity ([@bib7]; [@bib55]; [@bib4]; [@bib29]). While these observations are often interpreted as evidence of amyloid resolution, existing protein has not been demonstrated to transition from an amyloid to a non-amyloid form in any of the studies. Instead, two correlations have been observed where the reduced proteotoxicity has been linked to a change in amyloid state. Either amyloid accumulation is enhanced by chaperone overexpression ([@bib16]; [@bib12]), or amyloid accumulation is reduced. In the few cases where the mechanism has been determined, the reduction in amyloid accumulation results from an inhibition of amyloid assembly by the overexpressed chaperone ([@bib43]; [@bib71]; [@bib79]; [@bib75]; [@bib94]). Thus, even the specific overexpression of individual chaperones is unable to extend the proteostasis upper boundary in vivo to resolve protein amyloids.

Although these targeted interventions have yet to succeed, studies conducted under conditions that reduce amyloid amplification indicate that amyloid clearance may not represent an insurmountable obstacle. For example, repressing expression of an amyloidogenic protein can reverse established toxicity and, at least in some cases, clear existing amyloid ([@bib97]; [@bib52]; [@bib47]). In addition, expression of a dominant-negative mutant also promotes disassembly of wild-type amyloid in vivo ([@bib15]). Together, these observations suggest that amyloid clearance mechanisms exist in vivo, and indeed amyloid resolution is biochemically feasible in vitro using purified chaperones such as yeast Hsp104, alone or in combination with its co-chaperones Hsp40, Hsp70, and small heat shock proteins ([@bib30]; [@bib74], [@bib50]; [@bib75]). What limitations, then, restrict the ability of cells to expand proteostasis capacity to effectively resolve continuously expressed wild-type protein amyloids in vivo?

To identify cell-based limitations on proteostasis capacity, we focused on the mechanisms controlling persistence of the yeast prion \[*PSI*^*+*^\], the alternative, self-templating, amyloid form of the Sup35 protein ([@bib10]; [@bib62]; [@bib63]; [@bib25]; [@bib40]). In this study, we report that a transient thermal stress surprisingly leads to the complete disassembly of existing Sup35 amyloid. This process requires the accumulation of heat-induced non-prion protein aggregates in cells primarily at the later stages of the cell cycle. The engagement of Hsp104 with these substrates, and its inability to resolve them before cell division, leads to asymmetric retention of the chaperone in cells that experienced the thermal stress. As a result, Hsp104 accumulates to a level that is sufficient to resolve amyloid aggregates. Thus, the kinetics of substrate engagement by a PQC factor and its partitioning during cell division impose cell-based limitations on proteostasis capacity.

Results {#s2}
=======

Sup35 amyloid is resolubilized by Hsp104 following thermal stress {#s2-1}
-----------------------------------------------------------------

Under normal growth conditions, \[*PSI*^*+*^\] propagates faithfully ([@bib10]; [@bib14]). However, at elevated temperatures where the PQC capacity is increased, \[*PSI*^*+*^\] becomes destabilized in a Sup35 conformation-specific manner. For example, the more thermodynamically stable but less efficiently propagated \[*PSI*^*+*^\]^Weak^ variant is quantitatively 'cured' (i.e. converted to the non-prion \[*psi*^−^\] state) at elevated temperature in comparison with \[*PSI*^*+*^\]^Strong^, whose propagation is unaltered under the same conditions ([@bib11]; [@bib14]; [@bib35]; [@bib80]; [@bib58]). This curing of \[*PSI*^*+*^\]^Weak^ was linked to the inhibition of the molecular chaperone Hsp104 ([@bib58]), an observation that is seemingly counter to the idea that proteostasis capacity increases in response to stress ([@bib56]). However, in this study, stationary phase cultures were only briefly diluted into fresh medium to re-establish exponential growth before exposure to elevated temperature ([@bib58]). Because stationary phase alters chaperone expression and blocks \[*PSI*^*+*^\] curing at elevated temperature ([@bib23]; [@bib58]), residual effects from the growth phase switch could alter the interaction between Sup35 aggregates and PQC factors. Therefore, we revisited the effects of elevated temperature on \[*PSI*^*+*^\] propagation, beginning with exponentially growing cultures.

To monitor transitions from the prion \[*PSI*^*+*^\] to the non-prion \[*psi*^−^\] state, we used yeast strains encoding a premature termination codon (PTC) in the *ADE1* gene. In \[*PSI*^*+*^\] strains, Sup35 is functionally compromised, leading to stop-codon read-through and the formation of white or pink colonies on rich medium, but in \[*psi*^−^\] strains, termination is faithful at the PTC, leading to the formation of red colonies on rich medium ([@bib7]). Transiently elevating the growth temperature from 30°C to 40°C had no effect on viability ([Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}) or on \[*PSI*^*+*^\]^Strong^ propagation ([Figure 1A](#fig1){ref-type="fig"}) but induced \[*PSI*^*+*^\]^Weak^ curing ([Figure 1A,B](#fig1){ref-type="fig"}). Notably, both fully red and sectored colonies were observed, indicating that curing happened during both the thermal stress and subsequent recovery ([Figure 1B](#fig1){ref-type="fig"}). Thus, \[*PSI*^*+*^\]^Weak^ propagation is similarly sensitive to elevated temperature in exponentially growing cultures and in those that have recently exited stationary phase.10.7554/eLife.04288.003Figure 1.Thermal stress induces curing through resolution of Sup35 amyloid.(**A**) \[*PSI*^+^\]^Strong^ (SLL2606) and \[*PSI*^+^\]^Weak^ (SLL2600) cultures were incubated for 30 min at the indicated temperatures before plating on rich medium at 30°C to analyze curing by colony color phenotype, as described in the text. (**B**) Quantification of \[*PSI*^+^\]^Weak^ (SLL2600) colony color phenotypes following treatment as described in (**A**). Colonies were scored as completely \[*psi*^−^\] (black), or sectored (partially \[*psi*^−^\], white). Data represent averages; error bars represent standard deviations; n = 3. (**C**) Semi-native lysates of \[*psi*^−^\] (SLL2119), \[*PSI*^+^\]^Weak^ (SLL2600), and \[*PSI*^+^\]^Strong^ (SLL2606) cultures were analyzed by semi-denaturing detergent agarose gel electrophoresis (SDD-AGE) and immunoblotting for Sup35 after treatment as described in (**A**). (**D**) Sup35 released from amyoid aggregates in a \[*PSI*^*+*^\]^Weak^ strain (SLL2600) following treatment as described in (**A**) and recovery at 30°C in the presence of cycloheximide was determined by treating lysates with 2% SDS at 53°C, followed by SDS-PAGE and quantitative immunoblotting for Sup35. Lines represent medians; boxes represents upper and lower quartiles, and whiskers represent maximum and minimum; n = 5; \*p = 0.02, \*\*p = 0.01 by paired t-test.**DOI:** [http://dx.doi.org/10.7554/eLife.04288.003](10.7554/eLife.04288.003)10.7554/eLife.04288.004Figure 1---figure supplement 1.Characterization of thermal stress effects.(**A**). Exponentially growing \[*PSI*^+^\]^Weak^ cultures (SLL2600) were incubated at 30°C, 37°C, 40°C, or 37°C before 40°C for 30 min and plated to YPD at 30°C to quantify colony forming units. Data represent means; error bars represent standard deviations; n ≥ 3. (**B**) \[*PSI*^+^\]^Weak^ cultures (SLL2600) grown exponentially for 2 hr after dilution from a saturated overnight culture (left) or for at least 24 hr (right) were incubated at 40°C for 30 min and allowed to recover for 2 hr at 30°C. Lysates isolated from these cultures were analyzed by SDD-AGE and immunoblotting for Sup35.**DOI:** [http://dx.doi.org/10.7554/eLife.04288.004](10.7554/eLife.04288.004)

At the normal growth temperature, large Sup35 aggregates are fragmented into smaller complexes by Hsp104 ([@bib7]; [@bib19]; [@bib57]; [@bib69]; [@bib38]). In a culture that recently exited stationary phase, the size of SDS-resistant Sup35 aggregates increased, as assessed by semi-denaturing detergent agarose gel electrophoresis (SDD-AGE) ([@bib45]), following incubation at 40°C and a 2 hr recovery at 30°C ([Figure 1---figure supplement 1B](#fig1s1){ref-type="fig"}, left) ([@bib58]), consistent with an inhibition of fragmentation ([@bib58]). In contrast, SDS-resistant Sup35 aggregates were immediately reduced in size ([Figure 1C](#fig1){ref-type="fig"}, [Figure 1---figure supplement 1B](#fig1s1){ref-type="fig"}) and completely lost after recovery ([Figure 1---figure supplement 1B](#fig1s1){ref-type="fig"}, right) following identical treatment of an exponentially growing \[*PSI*^*+*^\]^Weak^ strain, a progression suggesting the resolution of existing Sup35 aggregates. To test this possibility, we incubated a \[*PSI*^*+*^\]^Weak^ culture at 40°C, returned the culture to 30°C in the presence of cycloheximide to repress new protein synthesis, and monitored the conversion of existing Sup35 from the amyloid \[*PSI*^*+*^\] state (i.e. SDS-resistant) to the non-amyloid \[*psi*^−^\] state (i.e. SDS-sensitive) ([@bib72]; [@bib70]). In a control culture at 30°C, very little pre-existing Sup35 transitioned to an SDS-sensitive state despite the inhibition of new protein synthesis ([Figure 1D](#fig1){ref-type="fig"}), as expected ([@bib15]). However, following incubation at 40°C, over 70% of SDS-resistant Sup35 became detergent sensitive during recovery at 30°C ([Figure 1D](#fig1){ref-type="fig"}), indicating disassembly of existing Sup35 amyloid. To determine if the prion curing resulting from this disassembly was mediated by Hsp104, we chemically inhibited this factor with guanidine HCl (GdnHCl) treatment or reduced its dosage by creating a heterozygous disruption in a diploid strain ([@bib18]; [@bib36]; [@bib26]; [@bib46]; [@bib81]; [@bib100]), and in both cases, \[*PSI*^*+*^\]^Weak^ curing was reduced by more than 50% relative to the wild-type untreated strain ([Figure 2A,B](#fig2){ref-type="fig"}). Thus, Hsp104 promotes the disassembly of existing Sup35 amyloid in a \[*PSI*^*+*^\]^Weak^ strain following thermal stress.10.7554/eLife.04288.005Figure 2.Curing is mediated by Hsp104 and depends upon propagation efficiency.(**A**) \[*PSI*^+^\]^Weak^ cultures (SLL2600) were incubated at 40°C for 30 min in the absence (untreated) or presence of guanidine HCl (GdnHCl) and plated on YPD to quantify prion loss by colony color phenotype. Data represent means; error bars represent standard deviations; n = 3; p = 0.0004 by unpaired t-test. (**B**) A WT (*HSP104*/+; SY945) and a heterozygous disruption (*HSP104*/Δ; SY591) \[*PSI*^*+*^\]^Weak^ diploid strain were incubated at 40°C for 90 min and plated on YPD to quantify prion loss by colony color phenotype. Data represent means; error bars represent standard deviations; n = 3; p \< 0.0001 by unpaired t-test. (**C**) \[*PSI*^+^\]^Strong^ strains expressing an extra copy of either WT (SY1646) or G58D (SY1648) Sup35 were incubated at 40°C for 90 min and plated on YPD to quantify prion loss by colony color phenotype. Data represent means; error bars represent standard deviations; n = 4; p \< 0.0001 by unpaired t-test. (**D**) A WT (*SUP35*/+; SLL3071) and a heterozygous disruption (*SUP35/*Δ; SY957) diploid \[*PSI*^+^\]^Strong^ strain were incubated at 40°C for 90 min and plated on YPD to quantify prion loss by colony color phenotype. Data represent means; error bars represent standard deviations; n = 3; p \< 0.0001 by unpaired t-test.**DOI:** [http://dx.doi.org/10.7554/eLife.04288.005](10.7554/eLife.04288.005)

At elevated temperature, we noted that the size of SDS-resistant Sup35 aggregates is reduced in a \[*PSI*^*+*^\]^Strong^ strain ([Figure 1C](#fig1){ref-type="fig"}), although curing does not occur ([Figure 1A](#fig1){ref-type="fig"}). Because \[*PSI*^*+*^\]^Strong^ propagates more efficiently than \[*PSI*^*+*^\]^Weak^, the former may be protected from curing at elevated temperature if the rate of Sup35 assembly continued to outpace the rate of its disassembly, a scenario that should be reversed by reducing the efficiency of \[*PSI*^*+*^\]^Strong^ propagation. To test this idea, we subjected \[*PSI*^*+*^\]^Strong^ diploid strains heterozygous for either a Sup35 mutant (G58D) or for a Sup35 disruption, which both reduce propagation efficiency ([@bib13]; [@bib15]), to thermal stress. At 30°C, \[*PSI*^*+*^\] propagation is stable in both of these strains ([Figure 2C,D](#fig2){ref-type="fig"}); however at 40°C, both were now efficiently cured (e.g. ∼100% for WT/*G58D*, ∼60% for *SUP35/*Δ) ([Figure 2C,D](#fig2){ref-type="fig"}). These observations not only provide additional support for Sup35 amyloid disassembly as the mechanism of prion curing in response to thermal stress but also reveal that the inability of chaperones to resolve amyloid in vivo results from both the physical characteristics of these aggregates and cell-based limitations, which are bypassed in the distinct proteostasis niche created at elevated temperature.

The asymmetric retention of Hsp104 is required for curing {#s2-2}
---------------------------------------------------------

Elevated temperature induces protein misfolding, and the cell responds to this stress by elevating the expression of PQC factors ([@bib56]). To deconvolute the contributions of each of these events to \[*PSI*^*+*^\]^Weak^ curing, we took advantage of the fact that we could modulate the efficiency of curing with variations in temperature. For example, while exposure to 40°C induced quantitative \[*PSI*^*+*^\]^Weak^ curing, pretreatment at 37°C prior to exposure to 40°C slightly reduced curing ([Figure 1A,B](#fig1){ref-type="fig"}, compare proportion of fully cured colonies), and incubation at 37°C did not induce curing at all ([Figure 1A,B](#fig1){ref-type="fig"}). This failure to destabilize \[*PSI*^*+*^\]^Weak^ at 37°C corresponded to an increase in aggregate size ([Figure 1C](#fig1){ref-type="fig"}) and a decrease in Sup35 solubilization ([Figure 1D](#fig1){ref-type="fig"}) relative to growth at 40°C alone, indicating a temperature-dependent modulation of amyloid resolution.

To determine the molecular basis of these differences in curing efficiency, we first monitored the levels of Sup35, Hsp104, Ssa1/2 (Hsp70), and Sis1 (Hsp40) proteins, which have all been implicated in Sup35 amyloid fragmentation ([@bib10]; [@bib7]; [@bib76]; [@bib28]; [@bib85]; [@bib13]). By quantitative immunoblotting, neither Sup35 ([Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"}) nor chaperone levels ([Figure 3A](#fig3){ref-type="fig"}, [Figure 3---figure supplement 1B](#fig3s1){ref-type="fig"}) correlated with curing efficiency ([Figure 1A](#fig1){ref-type="fig"}), indicating that \[*PSI*^*+*^\]^Weak^ curing could not be explained by simple changes in protein expression. Indeed, the specific overexpression of Hsp104 alone from a galactose-inducible promoter to levels that parallel those achieved during thermal stress ([Figure 3A](#fig3){ref-type="fig"} and [Figure 3---figure supplement 1C](#fig3s1){ref-type="fig"}) induces ∼40% \[*PSI*^*+*^\]^Weak^ curing ([Figure 3---figure supplement 1D](#fig3s1){ref-type="fig"}, 1.5 gen) in comparison with the ∼95% \[*PSI*^*+*^\]^Weak^ curing induced by thermal stress ([Figure 1B](#fig1){ref-type="fig"}) ([@bib15], [@bib92]). Moreover, Hsp104 overexpression alone leads to an increase in the size of SDS-resistant Sup35 aggregates isolated from a \[*PSI*^*+*^\]^Weak^ strain ([@bib45]), as previously reported for \[*PSI*^*+*^\]^Strong^ ([Figure 3---figure supplement 1E](#fig3s1){ref-type="fig"}) ([@bib45]), but this outcome is in obvious contrast to the disassembly of Sup35 amyloid that we observe upon thermal stress ([Figure 1C,D](#fig1){ref-type="fig"}). Thus, thermal stress and chaperone overexpression induce distinct changes in prion propagation.10.7554/eLife.04288.006Figure 3.Heat-induced aggregate accumulation but not chaperone levels correlate with temperature.(**A**) A \[*PSI*^+^\]^Weak^ strain (SLL2600) was incubated at 30°C, 37°C, 40°C, or 37°C before 40°C for 30 min, and lysates were prepared and analyzed by SDS-PAGE and quantitative immunoblotting for Hsp104 (black), Ssa1 (gray), and Sis1 (white). Data represent means; error bars represent standard deviations; n ≥ 3. (**B**) Aggregates from lysates of a \[*PSI*^+^\]^Weak^ strain (SLL2600) following treatment as described in (**A**) were prepared and analyzed by differential centrifugation and Bradford assay. Data represent means; error bars represent standard error; n = 6; \*p = 0.0014, \*\*p = 0.0052 by paired t-test.**DOI:** [http://dx.doi.org/10.7554/eLife.04288.006](10.7554/eLife.04288.006)10.7554/eLife.04288.007Figure 3---figure supplement 1.Effects of thermal stress and Hsp104 on protein accumulation.(**A**) Lysates were isolated from \[*PSI*^+^\]^Weak^ strains (SLL2600) incubated at 30°C, 37°C, 40°C, or 37°C before 40°C for 30 min and analyzed by SDS-PAGE and quantitative immunoblotting for Sup35. Data represent means; error bars represent standard deviations; n = 4. (**B**) Lysates were isolated from \[*PSI*^+^\]^Weak^ strains (SLL2600) incubated at 30°C, 37°C, 40°C, or 37°C before 40°C for 30 min and analyzed by SDS-PAGE and quantitative immunoblotting for Hsp104, Ssa1, Sis1 or phosphoglycerate kinase (PGK) as a loading control (representative blot; see [Figure 3A](#fig3){ref-type="fig"} for quantification). (**C**) Lysates were isolated from a \[*PSI*^+^\]^Weak^ strain containing a galactose-inducible *HSP104* at the endogenous locus (SY1749) after galactose treatment and Hsp104 protein was quantified by SDS-PAGE and immunoblotting. Data represent means; error bars represent standard deviations; n = 3. (**D**) Galactose-inducible *HSP104* \[*PSI*^+^\]^Weak^ strains (SY1749) were grown in the presence of galactose for various times and plated on YPD for analysis of \[*PSI*^+^\] phenotype. Data represent means; error bars represent standard deviation; n = 3. (**E**) Lysates isolated from galactose-inducible *HSP104* \[*PSI*^+^\]^Strong^ (SY1748) or \[*PSI*^+^\]^Weak^ (SY1749) cultures treated as described in (**D**) were analyzed by SDD-AGE and immunoblotting for Sup35. (**F**) Lysates were isolated from \[*PSI*^+^\]^Strong^ (black) (SLL2606) and \[*psi*^−^\] (white) (SLL2119) strains that were treated as described in (**B**), and heat-induced protein aggregates were quantified following differential centrifugation and Bradford assay. Data represent means; error bars represent standard errors; n ≥ 5. (**G**) Lysates were isolated from a \[*PSI*^+^\]^Weak^ strain (SLL2600) that was incubated at 30°C or 40°C for 30 min in the absence (untreated) or presence of GdnHCl, and heat-induced protein aggregates were quantified following differential centrifugation and Bradford assay. Data represent means; error bars represent standard error; n = 3.**DOI:** [http://dx.doi.org/10.7554/eLife.04288.007](10.7554/eLife.04288.007)

We next assessed the accumulation of misfolded proteins following shifts in temperature to determine if this event correlated with \[*PSI*^*+*^\]^Weak^ curing efficiency. By differential centrifugation, protein aggregates accumulated independent of prion status at all elevated temperatures ([Figure 3B](#fig3){ref-type="fig"}, [Figure 3---figure supplement 1F](#fig3s1){ref-type="fig"}), but in contrast to chaperone expression ([Figure 3A](#fig3){ref-type="fig"}, [Figure 3---figure supplement 1B](#fig3s1){ref-type="fig"}), the severity of this accumulation was impacted by growth temperature. At 37°C, protein aggregation increased by less than 10% in comparison with a culture maintained at 30°C ([Figure 3B](#fig3){ref-type="fig"}, column 1), but in cultures treated at 37°C followed by 40°C or directly at 40°C, this level rose to ∼20% or ∼40%, respectively ([Figure 3B](#fig3){ref-type="fig"}, columns 3 and 2). Thus, the accumulation of protein aggregates ([Figure 3B](#fig3){ref-type="fig"}) correlates directly with curing efficiency at the various temperatures ([Figure 1A](#fig1){ref-type="fig"}).

We noted, however, that this correlation was not observed for a \[*PSI*^*+*^\]^Weak^ culture treated with GdnHCl during a 40°C incubation, which strongly reduced curing efficiency ([Figure 2A](#fig2){ref-type="fig"}) but did not reduce the accumulation of protein aggregates ([Figure 3---figure supplement 1G](#fig3s1){ref-type="fig"}). Nevertheless, numerous studies have reported the localization of chaperones to cytoplasmic quality control foci upon exposure to proteotoxic stresses ([@bib1]; [@bib21]; [@bib37]; [@bib77]; [@bib95]), and GdnHCl blocks the association of Hsp104 with at least one substrate ([@bib94]). To determine if Hsp104 localization to heat-induced aggregates rather than their accumulation per se determined prion-curing efficiency, we replaced endogenous *HSP104* with an *HSP104-GFP* fusion, which supports \[*PSI*^*+*^\] propagation ([Figure 4---figure supplement 1A](#fig4s1){ref-type="fig"}). At 40°C, this strain exhibited time-dependent \[*PSI*^*+*^\]^Weak^ curing ([Figure 4---figure supplement 1B](#fig4s1){ref-type="fig"}) and accumulated protein aggregates ([Figure 4---figure supplement 1C](#fig4s1){ref-type="fig"}) and Hsp104-GFP to wild-type levels, albeit with slightly delayed kinetics ([Figure 4---figure supplement 1D](#fig4s1){ref-type="fig"}). At elevated temperatures, we observed an increase Hsp104-interacting proteins as assessed by co-immunocapture ([Figure 4A](#fig4){ref-type="fig"}) and the localization of Hsp104-GFP to cytoplasmic foci ([Figure 4B,C](#fig4){ref-type="fig"}), which also contain the model substrate firefly luciferase-mCherry ([Figure 4---figure supplement 1E](#fig4s1){ref-type="fig"}). The amount of co-immunocaptured proteins ([Figure 4A](#fig4){ref-type="fig"} \[2.5-fold increase at 37°C and 4.2-fold increase at 40°C relative to 30°C\]) and the number and intensity of Hsp104-GFP fluorescent foci ([Figure 4C](#fig4){ref-type="fig"}) corresponded to both the accumulation of heat-induced protein aggregates ([Figure 3B](#fig3){ref-type="fig"}) and the efficiency of curing ([Figure 1A](#fig1){ref-type="fig"}). Notably, the Hsp104-GFP fluorescence pattern was unaltered in a non-prion \[*psi*^−^\] strain ([Figure 4B](#fig4){ref-type="fig"}), indicating that Hsp104-GFP was engaged with non-prion substrates. Treatment of a \[*PSI*^*+*^\]^Weak^ culture with GdnHCl during an incubation at 40°C, which strongly reduces Hsp104-GFP association with heat-induced interacting proteins ([Figure 4A](#fig4){ref-type="fig"} \[1.7-fold decrease relative to 40°C in the absence of GdnHCl\]) and localization to cytoplasmic foci ([Figure 4---figure supplement 1F](#fig4s1){ref-type="fig"}), also reduces the efficiency of curing ([Figure 2A](#fig2){ref-type="fig"}, [Figure 4---figure supplement 1G](#fig4s1){ref-type="fig"}). Thus, the specific engagement of Hsp104 with heat-induced aggregates, rather than simply their presence, correlates with curing at elevated temperature.10.7554/eLife.04288.008Figure 4.Hsp104 engages heat-induced substrates upon thermal stress.(**A**) A \[*PSI*^+^\]^Weak^ strain with a GFP-tagged endogenous Hsp104 (SY2126) was incubated at 30°C, 37°C, 40°C, or 40°C with GdnHCl for 30 min, and immunocapture in the presence (+) or absence (−) of anti-GFP antibodies (Ab) was performed on native lysates. Proteins were analyzed by SDS-PAGE and general protein staining (Flamingo, top), or immunoblotting for GFP (bottom). (**B**) \[*PSI*^+^\]^Weak^ (SY2126) or \[*psi*^−^\] (SY2125) *HSP104GFP* strains were incubated at 30°C, 37°C, 40°C, or 37°C before 40°C for 90 min, and the pattern of Hsp104-GFP fluorescence was examined by microscopy. Scale bar = 1 μm. (**C**) Quantification of Hsp104-GFP fluorescence pattern in \[*PSI*^+^\]^Weak^ (SY2126) cells, treated as described in (**B**): no localization (white); single dot (light gray); faint aggregate (medium gray); bright aggregate (dark gray); multiple bright aggregates (black); n \> 25.**DOI:** [http://dx.doi.org/10.7554/eLife.04288.008](10.7554/eLife.04288.008)10.7554/eLife.04288.009Figure 4---figure supplement 1.Characterization of HSP104GFP strain.(**A**) \[*PSI*^+^\]^Weak^ (SLL2600) and \[*PSI*^+^\]^Weak^ *HSP104GFP* (SY2126) strains were grown at 30°C, plated on YPD, and incubated at 30°C for analysis of \[*PSI*^+^\] colony color phenotype. (**B**) \[*PSI*^+^\]^Weak^ (SLL2600, gray) and \[*PSI*^+^\]^Weak^ *HSP104GFP* (SY2126, white) strains were incubated at 40°C for the indicated times and plated on YPD at 30°C for analysis of prion curing by colony color phenotype. Data represent means; error bars represent standard deviations; n = 3.(**C**) Lysates were isolated from WT (SLL2600) or *HSP104GFP* (SY2126) \[*PSI*^+^\]^Weak^ strains that were incubated at 30°C or 40°C for 30 min, and heat-induced protein aggregates were quantified by differential centrifugation and Bradford assay. Data represent means; error bars represent standard error; n = 3. (**D**) Quantitative western blotting for Hsp104 was performed on lysates from \[*PSI*^+^\]^Weak^ (SLL2600) and \[*PSI*^+^\]^Weak^ *HSP104GFP* (SY2126) strains after incubation at 40°C for the indicated times. Data represent means; error bars represent standard deviations; n = 3. (**E**) Hsp104GFP and an mCherry-tagged firefly-luciferase (FFLmCh) reporter were visualized in a \[*PSI*^+^\]^Weak^ strain (SY2802) by microscopy following incubation at 30°C or after a 30-min recovery from an incubation at 40°C for 90 min (30°C→40°C). Scale bar = 1 μm. (**F**) Hsp104GFP was visualized in a \[*PSI*^+^\]^Weak^ strain (SY2126) by microscopy after a 90-min recovery from incubation at 40°C for 90 min in the absence (40°C) or presence of GdnHCl added before (GdnHCl→40°C) or after (40°C→GdnHCl) heat treatment. Scale bar = 1 μm. (**G**) \[*PSI*^+^\]^Weak^ *HSP104GFP* cultures (SY2126) treated as described in (**F**) were plated on YPD and incubated at 30°C for analysis of \[*PSI*^+^\] colony color phenotype. Data represent means; error bars represent standard deviations; n = 3; \*p = 0.0001,\*\*p = 0.0089.**DOI:** [http://dx.doi.org/10.7554/eLife.04288.009](10.7554/eLife.04288.009)

How does this chaperone engagement with heat-induced aggregates lead to the resolution of Sup35 amyloid? One possibility is that the asymmetric localization of Hsp104, resulting from its engagement with heat-induced protein aggregates ([@bib21]), increases its accumulation in a subpopulation of cells beyond that which can be achieved by its transcriptional up-regulation. To test this possibility, we first monitored the partitioning of Hsp104-GFP during cell division following incubation at various temperatures using microfluidics and fluorescence microscopy. Starting with budded cells, mother cells accumulated ∼60% of Hsp104-GFP following the completion of cell division at 30°C ([Figure 5A](#fig5){ref-type="fig"}, gray), which is comparable to the accumulation of untagged GFP expressed from the same promoter ([Figure 5---figure supplement 1A](#fig5s1){ref-type="fig"}) and thus likely reflects the volume differences between mother and daughter cells. This baseline asymmetry progressively increased as the temperature was increased to 37°C (∼65% retention), 37°C followed by 40°C (∼73% retention), and finally 40°C (∼75% retention; [Figure 5A](#fig5){ref-type="fig"}, gray). Notably, both Ssa1-GFP and Sis1-GFP fusions also localized to cytoplasmic, and, in the case of Sis1, nuclear foci ([Figure 5---figure supplement 1B,C](#fig5s1){ref-type="fig"}), but neither was asymmetrically retained following incubation at 40°C ([Figure 5---figure supplement 1D,E](#fig5s1){ref-type="fig"}), although their levels were elevated relative to 30°C ([Table 1](#tbl1){ref-type="table"}) due to their enhanced expression ([Figure 3A](#fig3){ref-type="fig"}). Thus, curing efficiency ([Figure 1A,B](#fig1){ref-type="fig"}) correlates directly with the asymmetric retention of Hsp104 in cells at elevated temperature.10.7554/eLife.04288.010Figure 5.Curing results from the asymmetric localization of Hsp104 following thermal stress.(**A**) A \[*PSI*^+^\]^Weak^ *HSP104GFP* culture (SY2126) was imaged over time in a microfluidics chamber at 30°C after a 30 min incubation at 30°C, 37°C, 40°C, or 37°C before 40°C. Fluorescence intensity in daughter and mother cells was quantified at the first cell division in cells that were budded (gray) or unbudded (orange) after thermal stress. Lines represent medians; boxes represent upper and lower quartiles, and whiskers represent maximum and minimum. All pairwise comparisons are significantly distinct, with a p \< 0.015, except where indicated (N.S.), by unpaired t-test; n ≥ 10. (**B**) A \[*PSI*^+^\]^Weak^ *HSP104GFP* WT (SY2126, gray) or *BNI1* deletion strain (Δ*bni1*) (SY2486, green) was imaged over time in a microfluidics chamber at 30°C after a 30 min incubation at 40°C. Fluorescence intensity in daughter and mother cells was quantified at the first cell division. Lines represent medians; boxes represent upper and lower quartiles; and whiskers represent maximum and minimum; n ≥ 14; p = 0.0075 by unpaired t-test. (**C**) \[*PSI*^+^\]^Weak^ WT (SLL2600) or Δ*bni1* strains (SY1888), treated as described in (**B**), were plated on YPD to analyze curing by colony color phenotype. Data represent means; error bars represent standard deviations; n = 3; p \< 0.0001 by unpaired t-test. (**D**) A \[*PSI*^+^\]^Weak^ *HSP104GFP* strain (SY2126) was imaged over time in a microfluidics chamber at 30°C after a 30 min incubation at 40°C and with GdnHCl added before or after the 40°C incubation. Fluorescence intensity in daughter and mother cells was quantified at the first cell division. Lines represent medians; boxes represent upper and lower quartiles; and whiskers represent maximum and minimum; n \> 11; \*p = 0.0003, \*\*p = 0.0026 by unpaired t-test. (**E**) A \[*PSI*^+^\]^Weak^ strain (SLL2600) was incubated at 40°C for 30 min and plated on rich medium. Mother and daughter pairs were separated by micromanipulation and allowed to form colonies, which were then dispersed to YPD for analysis of curing by colony color phenotype. n = 15. (**F**) A \[*PSI*^+^\]^Weak^ *HSP104GFP* culture (SY2126) was incubated at 30°C (dotted) or at 40°C for 30 min and allowed to recover for 30 min at 30°C (solid) before analysis of GFP fluorescence intensity by flow cytometry. Based on these intensities, cells were sorted into four fractions (orange, blue, purple, red) by FACS. (**G**) Cells collected in (**F**) were plated on YPD to analyze curing by colony color phenotype. Data represent means; error bars represent standard deviations; n = 2; \*p = 0.02 by paired t-test.**DOI:** [http://dx.doi.org/10.7554/eLife.04288.010](10.7554/eLife.04288.010)10.7554/eLife.04288.011Figure 5---figure supplement 1.Characterization of chaperone asymmetric retention following thermal stress.(**A**) A \[*psi*^−^\] strain expressing heat-inducible untagged GFP (SY2091) was imaged over time in a microfluidics chamber at 30°C after 30 min incubation at 40°C (red) or 30°C (gray). Fluorescence intensity in daughter and mother cells was quantified at the first cell division in budded cells. Lines represent medians, boxes represent upper and lower quartiles, and whiskers represent maximum and minimum; n ≥ 11. (**B**) A \[*PSI*^+^\]^Weak^ strain expressing a GFP-tagged endogenous Ssa1 and DsRedNLS (SY2659) was imaged after a 90 min incubation at 30°C, 37°C, 40°C, or 37°C before 40°C. Scale bar = 2 μm. (**C**) A \[*PSI*^+^\]^Weak^ strain expressing a GFP-tagged endogenous Sis1 and DsRedNLS (SY2485) was imaged after a 90-min incubation at 30°C, 37°C, 40°C, or 37°C before 40°C. Scale bar = 2 μm. (**D**) A \[*PSI*^+^\]^Weak^ *SSA1GFP* culture (SY2658) was imaged over time in a microfluidics chamber at 30°C after a 30 min incubation at 40°C (red) or 30°C (gray). Fluorescence intensity in daughter and mother cells was quantified at the first cell division in budded cells. Lines represent medians, boxes represent upper and lower quartiles, and whiskers represent maximum and minimum; n \> 15. (**E**) A \[*PSI*^+^\]^Weak^ *SIS1GFP* culture (SY2447) was imaged over time in a microfluidics chamber at 30°C after a 30 min incubation at 40°C (red) or 30°C (gray). Fluorescence intensity in daughter and mother cells was quantified at the first cell division in budded cells. Lines represent medians, boxes represent upper and lower quartiles, and whiskers represent maximum and minimum; n ≥ 7. (**F**) Quantitative immunoblotting for Hsp104 was performed on lysates from WT (SLL2600) or *Δbni1* (SY1888) \[*PSI*^+^\]^Weak^ cultures treated at 30°C (black) and 40°C (white) for 30 min following SDS-PAGE. Data represent means; error bars represent standard deviations; n = 3. (**G**) Lysates were isolated from WT (SLL2600) or *Δbni1* (SY1888) \[*PSI*^+^\]^Weak^ strains that were incubated at 30°C or 40°C for 30 min, and heat-induced protein aggregates were analyzed by differential centrifugation and Bradford assay. Data represent means; error bars represent standard error; n = 3.**DOI:** [http://dx.doi.org/10.7554/eLife.04288.011](10.7554/eLife.04288.011)10.7554/eLife.04288.012Table 1.Relative fluorescence intensity in mother cells**DOI:** [http://dx.doi.org/10.7554/eLife.04288.012](10.7554/eLife.04288.012)Treatment (°C)Hsp104 (Relative to 30°C)Ssa1 (Relative to 30°C)Sis1 (Relative to 30°C)30°→30°1 ± 0.1 (24)1 ± 0.2 (29)1 ± 0.1 (18)30°→37°1.6 ± 0.2 (11)30°→40°3.5 ± 0.6 (52)2.7 ± 0.5 (18)1.5 ± 0.1 (7)37°→40°3.4 ± 0.4 (46)[^4]

To determine if this correlation was a requirement, we next disrupted the asymmetric retention of Hsp104 and determined its effects on curing. Disruption of the formin *BNI1* ([@bib44]) did not alter Hsp104 expression levels or the accumulation of protein aggregates at 30°C and 40°C relative to a wild-type strain, ([Figure 5---figure supplement 1F,G](#fig5s1){ref-type="fig"}) but, Hsp104 asymmetric retention was reduced ([Figure 5B](#fig5){ref-type="fig"}, green), as expected ([@bib49]). Strikingly, curing was dramatically suppressed from ∼80% for a wild-type strain to ∼10% in the Δ*bni1* strain ([Figure 5C](#fig5){ref-type="fig"}). Likewise, GdnHCl treatment before thermal stress, which blocked both Hsp104 engagement with heat-induced aggregates ([Figure 4---figure supplement 1F](#fig4s1){ref-type="fig"}) and curing at elevated temperature ([Figure 2A](#fig2){ref-type="fig"}, [Figure 4---figure supplement 1G](#fig4s1){ref-type="fig"}), also reduced Hsp104-GFP asymmetric retention following exposure to 40°C ([Figure 5D](#fig5){ref-type="fig"}). Thus, the asymmetric retention of Hsp104 is required for curing.

Our single-cell analyses of Hsp104-GFP partitioning indicated that a relatively minor change in chaperone retention from 65% to 75%, which corresponded to a 2.2-fold increase in accumulation based on fluorescence intensity (compare 37°C--40°C, [Table 1](#tbl1){ref-type="table"}, [Figure 5A](#fig5){ref-type="fig"}), correlated with a quantitative switch from prion stability to curing ([Figure 1A,B](#fig1){ref-type="fig"}), suggesting the existence of a biological threshold in this range. To determine directly if cells accumulating Hsp104-GFP corresponded to those cured of \[*PSI*^*+*^\]^Weak^, we incubated a \[*PSI*^*+*^\]^Weak^ culture at 40°C and then isolated single unbudded cells on rich solid medium at 30°C. Following budding and cell division, mother and daughter cells were separated by micromanipulation and grown into colonies, which were then dispersed on rich solid medium to quantify prion retention. Mother cells, which experienced the elevated temperature and accumulated Hsp104 ([Figure 5A](#fig5){ref-type="fig"}), were more likely to be cured than their daughters ([Figure 5E](#fig5){ref-type="fig"}, note most data points fall below the diagonal), as predicted by our hypothesis. To more quantitatively correlate Hsp104-GFP accumulation with curing efficiency, we analyzed the distribution of Hsp104-GFP in a population of cells by flow cytometry. At 30°C, Hsp104-GFP fluorescence was distributed normally in the population ([Figure 5F](#fig5){ref-type="fig"}, dotted). Following incubation at 40°C, Hsp104-GFP fluorescence intensity in the population increased and its distribution was heterogeneous ([Figure 5F](#fig5){ref-type="fig"}, solid). When these subpopulations were separated by FACS and analyzed for colony-based phenotype, the efficiency of curing correlated directly with the accumulation of Hsp104-GFP ([Figure 5F,G](#fig5){ref-type="fig"}). Together, these observations indicate that cells exposed to elevated temperature accumulate heat-induced protein aggregates, asymmetrically retain Hsp104 in a manner that is proportional to these substrates, and ultimately cure \[*PSI*^*+*^\]^Weak^.

But, is Hsp104 enzymatic activity required for this curing, or is its asymmetric localization alone sufficient? As noted above, when cells are treated with GdnHCl before thermal stress, Hsp104 localization to cytoplasmic foci and asymmetric retention are both reduced ([Figure 5D](#fig5){ref-type="fig"}, [Figure 4---figure supplement 1F](#fig4s1){ref-type="fig"}). However, we reasoned the Hsp104 association with its substrates would be dynamic and modulated by its ATPase cycle. Indeed, blocking the ATPase activity of Hsp104 after thermal stress with a 90-min treatment with GdnHCl failed to reduce Hsp104-GFP localization to cytoplasmic foci ([Figure 4---figure supplement 1F](#fig4s1){ref-type="fig"}) or its asymmetric retention ([Figure 5D](#fig5){ref-type="fig"}), presumably because the chaperone bound to heat-induced substrates but was unable to release them once inhibited with GdnHCl. Despite the asymmetric localization of Hsp104-GFP under these conditions, \[*PSI*^*+*^\]^Weak^ curing was reduced by nearly 50% ([Figure 4---figure supplement 1G](#fig4s1){ref-type="fig"}). Thus, both Hsp104 asymmetric localization and activity are required to induce \[*PSI*^*+*^\]^Weak^ curing following thermal stress.

Cell-cycle stage and substrate-chaperone dynamics impact amyloid resolution {#s2-3}
---------------------------------------------------------------------------

The distribution of Hsp104-GFP in a population of \[*PSI*^*+*^\]^Weak^ cells that had been exposed to 40°C was very complex in contrast to the normal distribution of Hsp104-GFP at 30°C ([Figure 5F](#fig5){ref-type="fig"}), suggesting that subpopulations of cells were differentially retaining the chaperone. One source of heterogeneity in the population was cell-cycle stage, as our experiments used asynchronous cultures ([Figure 6A](#fig6){ref-type="fig"}). To determine if cell-cycle stage at the time of thermal stress impacted Hsp104 partitioning and explained this heterogeneity, we arrested cells in G1 with α-factor or at the G2/M transition with nocodazole ([@bib2]), exposed these cultures to 40°C incubation, and analyzed them by flow cytometry. Treatment with α-factor ([Figure 6B](#fig6){ref-type="fig"}) and nocodazole ([Figure 6C](#fig6){ref-type="fig"}) efficiently synchronized cultures at the non-budded or large-budded stages, respectively, and did not alter Hsp104 protein levels or localization relative to the asynchronous culture at 30°C ([Figure 6---figure supplement 1A,B](#fig6s1){ref-type="fig"}). At 40°C, Hsp104-GFP protein levels increased to similar extents in the asynchronous and arrested cultures ([Figure 6---figure supplement 1A](#fig6s1){ref-type="fig"}), and its localization to cytoplasmic foci was similar in all cases ([Figure 6---figure supplement 1B](#fig6s1){ref-type="fig"}). By flow cytometry, the distribution of Hsp104-GFP in the α-factor arrested culture remained normal ([Figure 6D](#fig6){ref-type="fig"}), but in the nocodazole-arrested culture, this distribution became bimodal ([Figure 6E](#fig6){ref-type="fig"}), indicating that Hsp104-GFP asymmetry is established immediately, even before cell division.10.7554/eLife.04288.013Figure 6.Efficient curing occurs in late cell-cycle staged cells following thermal stress.(**A**) Single cells from an asynchronous WT \[*PSI*^*+*^\]^Weak^ culture (SLL2600) were scored for morphology following bright-field imaging by microscopy: unbudded (black), tiny bud (dark gray), small bud (gray), medium bud (light gray), large bud (white). n = 153. (**B**) α-factor-arrested cultures were analyzed as in (**A**) over time after release. n ≥ 250. (**C**) Nocodazole-arrested cultures were analyzed as in (**A**) over time after release. n ≥ 175. (**D**) A \[*PSI*^+^\]^Weak^ *HSP104GFP* strain (SY2126) released from α-factor arrest was incubated at 40°C (solid black lines) for 30 min before analysis by flow cytometry. 100,000 cells were analyzed per sample. (**E**) A \[*PSI*^+^\]^Weak^ *HSP104GFP* strain (SY2126) released from nocodazole arrest was incubated at at 40°C (black lines) for 30 min before analysis by flow cytometry. 100,000 cells were analyzed per sample. (**F**) α-factor-arrested cultures (SLL2600) were incubated at 40°C for 30 min immediately or 30 min after release, and curing was quantified by colony color phenotype after plating on YPD at 30°C. Data represent means; error bars represent standard deviations; n = 3; p = 0.0255 by unpaired t-test. (**G**) Nocodazole-arrested cultures (SLL2600) were incubated at 40°C for 30 min immediately or 30 min after release, and curing was quantified colony color phenotype after plating on YPD at 30°C. Data represent means; error bars represent standard deviations; n = 3; p = 0.0263 by unpaired t-test.**DOI:** [http://dx.doi.org/10.7554/eLife.04288.013](10.7554/eLife.04288.013)10.7554/eLife.04288.014Figure 6---figure supplement 1.Characterization of chaperone accumulation and engagement in arrested cultures.(**A**) Lysates were isolated from asynchronous, α-factor-arrested, or nocodazole-arrested \[*PSI*^+^\]^Weak^ cultures (SLL2600) following incubation at 30°C (black) or 40°C (white) for 30 min, and the levels of Hsp104 were determined by quantitative immunoblotting following SDS-PAGE. Data represent means; error bars represent standard deviations; n = 3. (**B**) Asynchronous, α-factor-arrested, and nocodazole-arrested \[*PSI*^+^\]^Weak^ *HSP104GFP* (SY2126) cultures were treated for 90 min at 30°C or 40°C and imaged by microscopy. Scale bar = 2 μm.**DOI:** [http://dx.doi.org/10.7554/eLife.04288.014](10.7554/eLife.04288.014)

We next assessed the impact of cell-cycle stage on \[*PSI*^*+*^\]^Weak^ curing at elevated temperature. Arrest, without exposure to elevated temperature, did not induce curing ([Figure 6F,G](#fig6){ref-type="fig"}). In α-factor arrested cells, exposure to 40°C at release inefficiently cured \[*PSI*^*+*^\]^Weak^ (∼15%; [Figure 6F](#fig6){ref-type="fig"}), but in nocodazole-arrested cells, curing was nearly quantitative (∼90%; [Figure 6G](#fig6){ref-type="fig"}) consistent with the asymmetric localization of Hsp104-GFP in the latter but not the former case ([Figure 6D,E](#fig6){ref-type="fig"}). These observations suggest that cells at the end of the cell cycle are more sensitive to curing at elevated temperature than those at the beginning of the cell cycle. To test this idea, we released cultures from arrest and, after 30 min of growth at 30°C, exposed them to 40°C. For the culture originally arrested with α-factor, sensitivity to curing at elevated temperature increased ([Figure 6F](#fig6){ref-type="fig"}) as cells progressed into the late stages of the cell cycle ([Figure 6B](#fig6){ref-type="fig"}), and for the culture originally arrested with nocodazole, this sensitivity declined ([Figure 6G](#fig6){ref-type="fig"}) with cell-cycle progression ([Figure 6C](#fig6){ref-type="fig"}). Thus, curing occurs most efficiently when cells at a late stage of the cell cycle are exposed to elevated temperature.

Our earlier experiments linked curing to the asymmetric retention of Hsp104 at elevated temperature ([Figure 5](#fig5){ref-type="fig"}). To determine if cell-cycle stage impacts this asymmetry, we analyzed Hsp104-GFP distribution in mother--daughter pairs resulting from the growth and division of unbudded cells isolated from asynchronous cultures that were exposed to elevated temperatures. In comparison with budded cells, Hsp104-GFP retention was significantly reduced at all temperatures when unbudded cells were exposed to elevated temperature, but the magnitude of the effect was most severe for conditions that induced curing (30°C→40°C and 37°C→40°C; [Figure 5A](#fig5){ref-type="fig"}, orange), indicating a cell-cycle stage dependence on Hsp104-GFP retention at elevated temperature.

Because cell-cycle stage did not obviously alter the engagement of Hsp104-GFP with protein aggregates accumulating at elevated temperature ([Figure 6---figure supplement 1B](#fig6s1){ref-type="fig"}), the more efficient partitioning of Hsp104-GFP and the reduced curing in unbudded cells could reflect the resolution of heat-induced protein aggregates and thereby the release of Hsp104-GFP during the extended time before cell division in comparison with budded cells. Indeed, nearly 100% of cells contained Hsp104-GFP foci immediately after thermal stress ([Figure 7A](#fig7){ref-type="fig"}) but only ∼80% still contained foci when cell division re-initiated ∼150 min after incubation at 40°C ([Figure 7A](#fig7){ref-type="fig"}). Thus, the relative timing of substrate release and cell division could contribute to Hsp104 asymmetric retention and thereby curing. Consistent with this idea, 60% of unbudded cells, which are inefficiently cured ([Figure 6F](#fig6){ref-type="fig"}), resolved Hsp104-GFP foci prior to cell division ([Figure 7B](#fig7){ref-type="fig"} \[165--210 min\], [Figure 7C](#fig7){ref-type="fig"}), allowing the partitioning of the chaperone ([Figures 7B and 5A](#fig5 fig7){ref-type="fig"}, orange). In budded cells, which are efficiently cured ([Figure 6G](#fig6){ref-type="fig"}), only ∼8% of cells had resolved heat-induced Hsp104-GFP foci by the time the cell divided ([Figure 7B](#fig7){ref-type="fig"} \[105 min\], [Figure 7C](#fig7){ref-type="fig"}), leading to the asymmetric retention of Hsp104-GFP ([Figures 7B and 5A](#fig5 fig7){ref-type="fig"}, gray). Together, these observations indicate that Hsp104 is retained in cells exposed to elevated temperature if it is unable to resolve its heat-induced substrates prior to cell division. Because sensitivity to curing at elevated temperature correlated with cell-cycle stage ([Figure 6F,G](#fig6){ref-type="fig"}) and Hsp104-GFP localization to these cytoplasmic foci ([Figure 5](#fig5){ref-type="fig"}), substrate--chaperone dynamics must create a temporal limitation on proteostasis capacity.10.7554/eLife.04288.015Figure 7.Substrate--chaperone engagement must exceed time to cell division to induce curing.(**A**) The number of \[*PSI*^*+*^\]^Weak^ *HSP104GFP* (SY2126) cells containing fluorescent foci was quantified in cultures recovering at 30°C over time following a 90 min incubation at 40°C (white). Colony forming units in these cultures were quantified by plating (black). Data represent means; error bars represent standard deviations; n = 3. (**B**) \[*PSI*^*+*^\]^Weak^ *HSP104GFP* cells (SY2126) treated for 30 min at 40°C and imaged over time in a microfluidics chamber are shown. Cells that were budded at the time of thermal stress are outlined in white, while unbudded cells are outlined in orange. Solid lines mark mothers, and dotted lines mark daughters. Scale bar = 1 µm. (**C**) A \[*PSI*^*+*^\]^Weak^ *HSP104GFP* strain (SY2126) was imaged over time in a microfluidics at 30°C after a 30 min incubation at 40°C chamber. Budded or unbudded cells were scored at the first cell division for the presence or absence of fluorescent aggregates. Data represent means; error bars represent standard deviations; n = 3; p = 0.0005 by unpaired t-test.**DOI:** [http://dx.doi.org/10.7554/eLife.04288.015](10.7554/eLife.04288.015)

Discussion {#s3}
==========

In *Saccharomyces cerevisiae*, expression of the molecular chaperone Hsp104, even at its low basal level, reduces organismal fitness at the normal growth temperature; however, survival at elevated temperatures is absolutely dependent on Hsp104, whose expression is induced to high levels by heat shock ([@bib68]; [@bib22]). Thus, cell-based limitations must finely tune proteostasis capacity not only to control protein misfolding induced by stress but also to allow normal protein folding in the absence of these challenges ([@bib55]). Using the yeast prion \[*PSI*^*+*^\] as a model to understand the in vivo interactions between amyloid and PQC pathways, we have uncovered one such pathway. While \[*PSI*^*+*^\]^Weak^ is mitotically stable at the normal growth temperature (∼3% loss) ([@bib14]), a transient sub-lethal thermal stress induces quantitative curing ([Figure 1](#fig1){ref-type="fig"} and [Figure 8](#fig8){ref-type="fig"}) through the disassembly of existing Sup35 amyloid by Hsp104 ([Figures 1, 2 and 8](#fig1 fig2 fig8){ref-type="fig"}). Our studies indicate that the increase in Hsp104 expression at elevated temperature alone is not sufficient to induce Sup35 amyloid resolution and \[*PSI*^*+*^\]^Weak^ curing ([Figures 1, 3](#fig1 fig3){ref-type="fig"}). Rather, Hsp104 must engage heat-induced protein aggregates for a period that exceeds the time to the next cell division ([Figures 7, 8](#fig7 fig8){ref-type="fig"}). As a result, Hsp104 is asymmetrically localized to the cells that experienced the thermal stress ([Figures 5, 8](#fig5 fig8){ref-type="fig"}), and this increase in chaperone accumulation, along with its activity, promotes curing in the same cells ([Figures 5, 8](#fig5 fig8){ref-type="fig"}). Thus, chaperone spatial engagement, substrate processing dynamics, and partitioning during cell division represent cell based limitations on proteostasis capacity.10.7554/eLife.04288.016Figure 8.Model for Sup35 amyloid resolubilization and curing upon thermal stress.Upon thermal stress, cellular proteins (green) misfold and aggregate, leading to the induction and recruitment of Hsp104 (barrel). If thermal stress occurs in unbudded cells (1), these aggregates are resolved prior to cell division, allowing the partitioning of Hsp104 to both mother (black) and daughter (gray) cells (left). If thermal stress occurs in budded cells (2), heat-induced aggregates persist upon cell division (3), leading to the asymmetric retention of Hsp104 in mother cells. Both heat-induced aggregates (green) and Sup35 amyloid (blue corkscrews) are resolved in cells accumulating high levels of Hsp104, leading to curing (red, 4).**DOI:** [http://dx.doi.org/10.7554/eLife.04288.016](10.7554/eLife.04288.016)

Metazoans lack an Hsp104 homolog ([@bib86]), but disaggregase activity has also recently been linked to a multi-component system in yeast comprised of Hsp110, Hsp70, and Hsp40, and this activity is conserved in the *C. elegans* and human homologs of these chaperones ([@bib73]; [@bib66]; [@bib53]). This system is largely ineffective in the disaggregation of amyloid in vitro ([@bib73]) but can promote the slow disassembly of amyloid from fiber ends in the presence of small heat shock proteins, such as Hsp26 and Hsp42 from yeast or HspB5 from humans ([@bib17]). Like Hsp104 in yeast, Hsp110 localizes to foci containing misfolded protein in human cells following thermal stress ([@bib66]) and interacts with protein amyloids in vivo ([@bib31]; [@bib91]; [@bib59]), raising the possibility that Hsp110 engagement with stress-induced substrates could also promote its activity toward amyloidogenic substrates in vivo.

The spatial engagement of PQC factors, including both chaperones and components of the ubiquitin--proteasome system, is a newly appreciated consequence of their function in vivo*.* Numerous cytoplasmic foci arise in response to stressors including heat, aging, oxidation, and/or proteasome inhibition. These foci include aggresomes, the insoluble protein deposit (IPOD), the juxtanuclear quality control compartment (JUNQ), StiF-inducible foci (StiF), and Q-bodies, the latter of which form under the mild thermal stress conditions employed in our studies ([@bib34]; [@bib21]; [@bib37]; [@bib49]; [@bib77]; [@bib51]; [@bib93]; [@bib22]; [@bib95]). While the relationship of each of these foci to one another is currently unclear, they are all defined by the co-localization of misfolded and/or aggregation-prone proteins with PQC factors, some of which can be found in more than one of type of focus. The PQC factors that localize to these foci, such as Hsp104, clearly promote survival under stress ([@bib68]; [@bib22]), but whether their localization into cytoplasmic foci specifically altered proteostasis capacity had not been previously established. Our studies indicate that the engagement of Hsp104 with heat-induced misfolded protein aggregates enhances proteostasis capacity by increasing the accumulation of this factor beyond the level attainable by changes in gene expression ([Figure 5](#fig5){ref-type="fig"}) and thereby permitting the disassembly of existing Sup35 amyloid ([Figures 1,5](#fig1 fig5){ref-type="fig"}).

While our studies indicate that chaperone partitioning imposes a limitation on proteostasis capacity, other aspects of this process may be more relevant to this upper boundary in post-mitotic cells, such as neurons. Indeed, our observations reveal other cell-based limitations beyond chaperone partitioning. For example, in contrast to the proteostasis enhancement we observe following thermal stress in yeast, previous studies have linked the accumulation of protein aggregates to reduced proteostasis capacity in vivo ([@bib4]). In these cases, protein aggregates, including those resulting from oxidative damage with age or proteotoxic stresses, have been linked to reduced replicative lifespan, ([@bib1]; [@bib27]; [@bib67]; [@bib21], [@bib20]; [@bib84]; [@bib42]; [@bib49]; [@bib89]; [@bib101]; [@bib78]) and, the presence of protein amyloids, such as polyglutamine-expanded proteins and other yeast prions, promote the misfolding of metastable proteins, interfere with proteolysis, reduce protein synthesis, inhibit endocytosis, and disrupt prion propagation through the sequestration of chaperones ([@bib24]; [@bib54]; [@bib41]; [@bib60]; [@bib98]; [@bib99]). A comparison of these studies with our work suggests that the dynamics of chaperone engagement with distinct substrates, rather than simply their presence, correlates with the impact of these interactions on proteostasis capacity. In the studies resulting in chaperone sequestration, proteotoxicity correlates with imbalances in the system imposed by harsh conditions and/or the unnaturally high expression of amyloidogenic proteins. In contrast, we detect no differences in Hsp104-GFP localization in \[*PSI*^*+*^\] and \[*psi*^−^\] strains expressing Sup35 at its endogenous level ([Figure 4A](#fig4){ref-type="fig"}, 30°C), and Sup35 amyloid can clearly be resolved at these native stoichiometries when the system is elevated to a distinct but accessible proteostatic niche ([Figure 1D](#fig1){ref-type="fig"}). However, paralleling the studies in metazoans, \[*PSI*^*+*^\] can transition from a benign to a toxic state upon Sup35 overexpression ([@bib83]), a condition that also induces Hsp70 co-localization ([@bib94]). Thus, proteostasis capacity appears to be finely tuned to maintain a natively expressed proteome.

Additional evidence of the importance of this balance can be gleaned by a comparison of chaperone overexpression in different cellular contexts. For example, overexpression of Hsp104 alone, to the same level achieved here through asymmetric retention of this factor ([Table 1](#tbl1){ref-type="table"} and [Figure 3---figure supplement 1C](#fig3s1){ref-type="fig"}), also induces curing ([@bib7]; [@bib92]). While it has been suggested that Hsp104 overexpression dissolves Sup35 amyloid in vivo, this interpretation is complicated by a lack of temporal resolution and the ability to monitor existing protein ([@bib61]) and is inconsistent with the increase in the size of SDS-resistant Sup35 aggregates under these conditions ([Figure 3---figure supplement 1D](#fig3s1){ref-type="fig"}) ([@bib45]). An alternative model, which is consistent with this biochemical evidence of Hsp104 inhibition, suggests that upon its overexpression, Hsp104 aberrantly and non-productively co-localizes with Sup35 amyloid ([@bib7]; [@bib45]; [@bib3]; [@bib94]). In contrast, our studies indicate that Hsp104 overexpression within the context of a thermal stress transitions Sup35 amyloid from outside the buffering capacity of the proteostasis network to within its sphere of protection. Notably, Hsp104 co-localization with Sup35 amyloid varies based on its mode of overexpression (i.e. individual vs network up-regulation), again implicating substrate--chaperone dynamics, rather than simply chaperone availability, in proteostasis capacity. Intriguingly, this interplay is distinct for individual PQC factors within the same cell, as thermal stress induces localization of Hsp104, Ssa1, and Sis1 to cytoplasmic foci, but only Hsp104 is asymmetrically retained upon cell division ([Figure 5---figure supplement 1D, E](#fig5s1){ref-type="fig"}), suggesting an additional point of proteostasis regulation.

Beyond these cell-based limitations on proteostasis capacity, our studies have deconvoluted the contributions of distinct physical characteristics of amyloid variants to their ability to exceed the PQC buffering capacity in vivo. Intriguingly, we find that \[*PSI*^*+*^\]^Weak^, the more thermodynamically stable but less efficiently amplified variant of Sup35 amyloid ([@bib80]), is susceptible to curing at elevated temperature, while the less thermodynamically stable and more efficiently amplified \[*PSI*^*+*^\]^Strong^ variant is not ([Figure 1](#fig1){ref-type="fig"}), indicating that amyloid amplification rather than stability imposes the primary limitation on amyloid clearance. Consistent with this idea, reducing \[*PSI*^*+*^\]^Strong^ amplification by either expressing a Sup35 mutant or decreasing the expression of wild-type Sup35 promotes curing at elevated temperature ([Figure 2](#fig2){ref-type="fig"}). Thus, manipulations that have minor effects on the dynamics of existing amyloid are also sufficient to move this alternative protein-folding pathway within the buffering capacity of the proteostasis network.

Together, our observations suggest an alternative to the view that the physical characteristics of amyloid complexes alone preclude their accessibility to the cell\'s natural defenses against protein misfolding. Rather, the dynamics and balance of the system as a whole, including both protein-based and cell-based contributors, create not only a niche that allows amyloid to arise and persist but also another that promotes amyloid clearance. Our studies, therefore, raise the possibility that the proteostasis limitations that allow the accumulation of chronically misfolded proteins may be distinct in a native context and under conditions of their overexpression. Within this framework, our studies provide a proof-of-principle example to support the idea that proteostasis regulators, which are aimed at transitioning proteostasis landscapes to new thresholds, may be the most effective interventions into amyloidosis ([@bib48]).

Materials and methods {#s4}
=====================

Plasmid and strain construction {#s4-1}
-------------------------------

All plasmids used in this study were previously reported ([Table 2](#tbl2){ref-type="table"}) except for SB1013 (pRS306P~GPD~-FFL-mCherry), which contains firefly luciferase as an *Xba1/BamHI* fragment and mCherry as a *BamHI/XhoI* fragment, separated by a three-repeat glycine--serine linker. The ORFs were amplified by PCR using primers 5XbaI firefly/3BamHI firefly and 5BamHIGS3mCherry/3XhoImCherry, respectively ([Table 3](#tbl3){ref-type="table"}) and confirmed by sequencing. All strains of *Saccharomyces cerevisiae* used in this study are derivatives of 74-D694 ([Table 4](#tbl4){ref-type="table"}) ([@bib7]). A WT \[*PSI*^+^\]^Weak^ diploid strain (SY945) was generated by mating SY2600 with SLL3252 ([Table 4](#tbl4){ref-type="table"}). The diploid state was confirmed by sporulation. SY591, a \[*PSI*^*+*^\]^Weak^ strain containing a heterozygous deletion of *HSP104*, was created by transformation of a *Pvu*I-*Bam*HI fragment of pYABL5 (a kind gift of S. Lindquist) into SY945 and selection on medium lacking leucine. Disruptions were verified by PCR and 2:2 marker segregation upon sporulation and dissection. SY957, a \[*PSI*^+^\]^Strong^ diploid strain containing a heterozygous disruption of *SUP35*, was created by transforming a PCR-generated cassette using pFA6a-KanMX4 as a template with primers SD27 and SD28 ([Table 3](#tbl3){ref-type="table"}) into SLL3071 ([Table 4](#tbl4){ref-type="table"}). Integration was confirmed by PCR using primers Psup352/PTEFCH and Sup35 3′chk/pFa6 test ([Table 3](#tbl3){ref-type="table"}). The galactose-inducible *HSP104* strains were made by integrating *BstBI*-linearized SB630 ([Table 2](#tbl2){ref-type="table"}) into SY197 ([Table 4](#tbl4){ref-type="table"}) and selecting transformants on medium lacking uracil. Galactose-inducible expression of Hsp104 was confirmed by western blotting. \[*PSI*^*+*^\]^Strong^ and \[*PSI*^*+*^\]^Weak^ were then cytoduced into this strain from SY1698 and SY1699, respectively, to create SY1748 and SY1749 ([Table 4](#tbl4){ref-type="table"}), respectively ([@bib9]). Cytoductants were selected by growth on synthetic medium containing glycerol and lacking uracil and by colony color on YPD. The *HSP104-GFP* \[*psi*^−^\] strain (SY2125) was created by transforming a PCR-generated cassette using pFA6a-GFP(S65T)-KanMX6 as a template with primers HSP104-GFP F-A and HSP104-GFP R-A ([Table 3](#tbl3){ref-type="table"}) into WT \[*PSI*^+^\]^Strong^ strains and selection on medium containing 300 μg/ml G418. Integration was confirmed by PCR using primers Hsp104for/GFP-R and pFa6 test/Hsp104 3 flank R ([Table 3](#tbl3){ref-type="table"}), and expression was confirmed by fluorescence microscopy. These strains were cured of the prion by growth on YPD plates containing 3 mM GdnHCl ([@bib87]). The \[*PSI*^+^\]^Weak^ variant (SY2126) was generated by mating SY2125 to a WT \[*PSI*^+^\]^Weak^ strain (SLL2600) and sporulation. Tetrads were dissected to recover haploids, and *HSP104-GFP* isolates were verified by G418 resistance, fluorescence microscopy, and quantitative immunoblotting for Hsp104. The heat inducible GFP strain (SY2091) was generated by transformation of a WT \[*psi*^−^\] strain (SLL2119) with *Bsu*36I-digested SB849 ([Table 2](#tbl2){ref-type="table"}). Expression was confirmed by fluorescence microscopy. *SSA1-GFP* (SY2658) and *SIS1-GFP* (SY2447) \[*PSI*^+^\]^Weak^ strains were created by transforming PCR-generated cassettes using pFA6a-GFP(S65T)-KanMX6 as a template with primers GFP-GS-Ssa1-F/GFP-Ssa1-R or Sis1-GFP-F GS/Sis1-GFP-R ([Table 3](#tbl3){ref-type="table"}), respectively, into WT \[*PSI*^+^\]^Strong^ strains and selection on medium containing 300 μg/ml G418. Expression was confirmed by fluorescence microscopy and quantitative immunoblotting for Ssa1/2 and Sis1, respectively. These strains were cured of the prion by growth on YPD plates containing 3 mM GdnHCl, mitochondrial loss was induced by growth in 25 μg/ml ethidium bromide, and \[*PSI*^*+*^\]^Weak^ was transferred to them by cytoduction ([@bib10]), using SY1699 as a donor strain. Cytoductants were selected by growth on glycerol medium and 300 μg/ml G418. *SSA1-GFP* and *SIS1-GFP* \[*PSI*^+^\]^Weak^ strains containing a nuclear-localized fluorescent reporter protein (DsRed-NLS, SY2659, and SY485, respectively) were generated by transforming SY2658 or SY2447 with *Bsu*36I-digested SB503 ([Table 2](#tbl2){ref-type="table"}). Expression was confirmed by fluorescence microscopy. The Δ*bni1* \[*PSI*^+^\]^Weak^ strain (SY1888) was created by transforming a PCR-generated cassette using pFA6a-KanMX4 as a template with primers AD-BNI1-f and AD-BNI1-r ([Table 3](#tbl3){ref-type="table"}) into a \[*PSI*^+^\]^Weak^ diploid (SY782, a cross between SY2600 and SY86, [Table 4](#tbl4){ref-type="table"}). Transformants were selected on medium containing 300 μg/ml G418 and verified by PCR using primers AD-BNI1-fseq/PTEFCH and AD-BNI1-rseq/pFa6 test ([Table 3](#tbl3){ref-type="table"}). The haploid Δ*bni1* \[*PSI*^+^\]^Weak^ strain was then generated by sporulation and tetrad dissection and verified by G418 resistance. The *HSP104-GFP* Δ*bni1* \[*PSI*^+^\]^Weak^ strain (SY2486) was created by transforming SY2126 with a PCR-generated cassette using pFA6a-hphMX4 as a template with primers AD-BNI1-f and AD-BNI1-r ([Table 3](#tbl3){ref-type="table"}). Transformants were confirmed by PCR using primers AD-BNI1-fseq/PTEFCH and AD-BNI1-rseq/pFa6 test ([Table 4](#tbl4){ref-type="table"}) and growth on YPD plates containing 300 μg/ml hygromycin B.10.7554/eLife.04288.017Table 2.Plasmids**DOI:** [http://dx.doi.org/10.7554/eLife.04288.017](10.7554/eLife.04288.017)NameDescriptionSB20pRS306-P~Sup35~N(GS)~3~sGFP(GS)~3~MCSB503pRS304-P~*GPD*~GST-DsRED-NLSSB630pRS306-P~*GAL*~Hsp104SB657pRS306-P~*tetO2*~Sup35SB658pRS306-P~*tetO2*~Sup35(G58D)SB849pRS306-P~*HSE*~GFPSB1013pRS306-P~*GPD*~FFL-mCherry10.7554/eLife.04288.018Table 3.Primers**DOI:** [http://dx.doi.org/10.7554/eLife.04288.018](10.7554/eLife.04288.018)NameSequence5XbaI firefly5′-TCTAGAATGGAAGATGCCAAAAACATTAAG-3′3BamHI firefly5′-GGATCCACCTTGAGACTGTGGTTGGAAAC-3′5BamHI GS3mCherry5′-GGATCCGGTAGTGGTAGTGGTAGTATGGTGAGCAAGGG CGAGGAG-3′3XhoI mCherry5′-CTCGAGTTACTTGTACAGCTCGTCCATGCCG-3′SD275′-ACTTGCTCGGAATAACATCTATATCTGCCCACTAGCAACA CAGCTGAAGCTTCGTACGC-3′SD285′-GGTATTATTGTGTTTGCATTTACTTATGTTTGCAAGAAATG CATAGGCCACTAGTGGATCTG-3′Psup3525′-GAGATGCTCATCAAGGG-3′PTEFCH5′-GCACGTCAAGACTGTCAAGG-3′Sup35 3′chk5′-TATTTACGAAGGAGACCCGGAG-3′pFa6 test5′-TGCCCAGATGCGAAGTTAAGTG-3′HSP104-GFP F-A5′-CGATAATGAGGACAGTATGGAAATTGATGATGACCTA GATCGGATCCCCGGGTTAATTAA-3′Hsp104-GFP R-A5′-TATTATATTACTGATTCTTGTTCGAAAGTTTTTAAAAATC GAATTCGAGCTCGTTTAAAC-3′Hsp104for5′-GGCACATCCTGATGTTTTGA-3′GFP-R5′-CCTTCACCCTCTCCACTGACAG-3′Hsp104 3 flank R5′-CCGTATTCTAATAATGGACCAATC-3′GFP-GS-Ssa1-F5′-AGCTCCAGAGGCTGAAGGTCCAACCGTTGAAGAAGTTG ATGGTTCTGGTTCTGGTTCTCGGATCCCCGGGTTAATTAA-3′GFP-Ssa1-R5′-ACCCAGATCATTAAAAGACATTTTCGTTATTATCAATTGC GAATTCGAGCTCGTTTAAAC-3′Sis1-GFP-F GS5′-ACTAAACGACGCTCAAAAACGTGCTATAGATGAAAATTT TGGTTCTGGTTCTGGTTCTCGGATCCCCGGGTTAATTAA-3′Sis1-GFP-R5′-ATTTATTTGAGTTTATAATTATATTTGCTTAGGATTACTAG AATTCGAGCTCGTTTAAAC-3′AD-BNI1-f5′-ATGTTGAAGAATTCAGGCTCCAAACATTCGAACTCAAAG GCAGCTGAAGCTTCGTACGC-3′AD-BNI1-r5′-TTATTTGAAACTTAGCCTGTTACCTGTCCTAGCCTCACCT GCATAGGCCACTAGTGGATCTG-3′AD-BNI1-fseq5′-GACATCGGTTAGAGGAAG-3′AD-BNI1-rseq5′-CACTGTGCTTGTCACTTA-3′10.7554/eLife.04288.019Table 4.Yeast strains**DOI:** [http://dx.doi.org/10.7554/eLife.04288.019](10.7554/eLife.04288.019)StrainGenotypePlasmids integratedReferenceFigureSLL2119*MATa* \[*psi*^−^\] *ade1-14 his3Δ200 trp1-289 ura3-52 leu2-3, 112*-[@bib7]1c, 3SfSLL2600*MATa* \[*PSI*^+^\]^Weak^ *ade1-14 his3Δ200 trp1-289 ura3-52 leu2-3, 112*-[@bib14]1, 2a, 3, 5ce, 6abcfg, 1S, 3Sabg, 4Sabcd, 5Sfg, 6SaSLL2606*MATa* \[*PSI*^+^\]^Strong^ *ade1-14 his3Δ200 trp1-289 ura3-52 leu2-3, 112*-[@bib7]1ac, 3SfSLL3071*MATa/α* \[*PSI*^+^\]^Strong^ *ade1-14/ade1-14 his3Δ200/his3Δ200 trp1-289/ trp1-289 ura3-52/ura3-52 leu2-3112/ leu2-3112*-[@bib15]2dSLL3252*MATa* \[*psi*^−^\] *ade1-14 his3Δ200 trp1-289 ura3-52 leu2-3, 112*-[@bib7]'Materials and methods'SY86*MATα* \[*psi*^−^\] *ade1-14 his3Δ200 trp1-289 ura3-52 leu2-3, 112 sup35::N(GS)*~*3*~*GFP(GS)*~*3*~*MC*SB20[@bib13]'Materials and methods'SY197*MATa* \[*psi*^−^\] *ade1-14 his3-11,-15 trp1-1 ura3-1 leu2-3112 can1-100*-J Weissman (YJW513)'Materials and methods'SY591*MATa/α* \[*PSI*^+^\]^Weak^ *ade1-14/ade1-14 his3Δ200/his3Δ200 TRP/ trp1-289 ura3-52/ura3-52 leu2-3112/ leu2-3112 HSP104/hsp104::LEU2*-This study2bSY782*MATa/α* \[*PSI*^+^\]^Weak^ *ade1-14/ade1-14 his3Δ200/his3Δ200 trp1-289/ trp1-289 ura3-52/ura3-52 leu2-3112/ leu2-3112 SUP35/sup35::N(GS)*~*3*~*GFP(GS)*~*3*~*MC*-This study'Materials and methods'SY945*MATa/α* \[*PSI*^+^\]^Weak^ *ade1-14/ade1-14 his3Δ200/his3Δ200 trp1-289/ trp1-289 ura3-52/ura3-52 leu2-3112/ leu2-3112*-This study2bSY957*MATa/α* \[*PSI*^+^\]^Strong^ *ade1-14/ade1-14 his3Δ200/his3Δ200 trp1-289/ trp1-289 ura3-52/ura3-52 leu2-3112/ leu2-3112 SUP35/sup35::KANMX4*-This study2dSY1646*MATa/α* \[*PSI*^+^\]^Strong^ *ade1-14/ade1-14 his3Δ200/his3Δ200 trp1-289/ trp1-289 ura3-52/ura3-52::URA3::P*~*tetO2*~*SUP35 leu2-3112/ leu2-3112 SUP35/sup35::KANMX4*SB657[@bib15]2cSY1648*MATa/α* \[*PSI*^+^\]^Strong^ *ade1-14/ade1-14 his3Δ200/his3Δ200 trp1-289/ trp1-289 ura3-52/ura3-52::URA3::P*~*tetO2*~*SUP35(G58D) leu2-3112/ leu2-3112 SUP35/sup35::KANMX4*SB658[@bib15]2cSY1698*MATα* \[*PSI*^+^\]^Strong^ *ade1-14 his3Δ200 ura3-52 leu2-3 kar1-d15 ConR CyhR*-This study'Materials and methods'SY1699*MATα* \[*PSI*^+^\]^Weak^ *ade1-14 his3Δ200 ura3-52 leu2-3 kar1-d15 ConR CyhR*-This study'Materials and methods'SY1748*MATa* \[*PSI*^+^\]^Strong^ *ade1-14 his3-11,-15 trp1-1 ura3-1::URA3::P*~*GAL*~*HSP104 leu2-3112 can1-100*SB630This study3SeSY1749*MATa* \[*PSI*^+^\]^Weak^ *ade1-14 his3-11,-15 trp1-1 ura3-1::URA3::P*~*GAL*~*HSP104 leu2-3112 can1-100*SB630This study3ScdeSY1888*MATa* \[*PSI*^+^\]^Weak^ *ade1-14 his3Δ200 trp1-289 ura3-52 leu2-3, 112 Δbni1::KANMX4*-This study5c, 5SfgSY2091*MATa* \[*psi*^−^\] *ade1-14 his3Δ200 trp1-289 ura3-52::URA::P*~*HSE*~*GFP leu2-3, 112*SB849This study5SaSY2125*MATα* \[*psi*^−^\] *ade1-14 his3Δ200 trp1-289 ura3-52 leu2-3112 HSP104GFP::KANMX6*-This study4bSY2126*MATa* \[*PSI*^+^\]^Weak^ *ade1-14 his3Δ200 trp1-289 ura3-52 leu2-3112 HSP104GFP::KANMX6*-This study4, 5abdfg, 6de, 7, 4Sabcdfg, 6SbSY2447*MATa* \[*PSI*^+^\]^Weak^ *ade1-14 his3Δ200 trp1-289 ura3-52 leu2-3112 SIS1GFP::KANMX6*-This study5SeSY2485*MATa* \[*PSI*^+^\]^Weak^ *ade1-14 his3Δ200 trp1-289::TRP::P*~*GPD*~*GST-DsRed-NLS ura3-52 leu2-3112 SIS1GFP::KANMX6*SB503This study5ScSY2486*MATa* \[*PSI*^+^\]^Weak^ *ade1-14 his3Δ200 trp1-289 ura3-52 leu2-3, 112 HSP104GFP::KANMX6 Δbni1::hphMX4*-This study5bSY2658*MATa* \[*PSI*^+^\]^Weak^ *ade1-14 his3Δ200 trp1-289 ura3-52 leu2-3112 SSA1GFP::KANMX6*-This study5SdSY2659*MATa* \[*PSI*^+^\]^Weak^ *ade1-14 his3Δ200 trp1-289::TRP::P*~*GPD*~*GST-DsRed-NLS ura3-52 leu2-3112 SSA1GFP::KANMX6*SB503This study5SbSY2802*MATa* \[*PSI*^+^\]^Weak^ *ade1-14 his3Δ200 trp1-289 ura3-52::URA::P*~*GPD*~*Firefly-mCherry leu2-3112 HSP104GFP::KANMX6*SB1013This study4Se

Growth conditions and phenotypic analysis {#s4-2}
-----------------------------------------

Unless otherwise specified, yeast cultures were grown in rich YPD medium supplemented with 0.3 mM adenine. Cultures were maintained at an OD~600~ of less that 0.5 at 30°C for at least 10 doublings to ensure exponential growth. Where indicated, cultures were then transferred to 37°C or 40°C for the specified period. Pretreatment of cultures at 37°C prior to shift to 40°C was for 30 min. To analyze colony color phenotype, aliquots of cultures were diluted in H~2~O as needed to ensure well-separated single colonies upon plating to solid YPD medium. After growth at 30°C, each colony was scored based on colony color phenotype: fully cured (completely red, \[*psi*^−^\]), sectored (part red and part white), or \[*PSI*^+^\] (completely white). Unless otherwise indicated, fully cured and sectored colonies were combined in the 'cured' category. For all colony counting assays, at least 150 colonies were counted for each experimental condition/timepoint. For the galactose-inducible Hsp104 experiments, cells were grown in rich YP medium containing 3% raffinose supplemented with 3% galactose during induction. α-factor and nocodazole arrests were performed in YPD liquid medium containing final concentrations of 5 μg/ml α-factor or 15 μg/ml nocodazole, respectively, for ∼2 hr. Following confirmation of arrest based on cell morphology by bright-field microscopy, cultures were washed three times with medium containing 1 mM DMSO followed by one wash in YPD before resuspension for indicated manipulation. GdnHCl treatment was performed at 3 mM final concentration in liquid YPD, and for experiments involving recovery, cultures were washed three times with medium before resuspension in YPD for indicated manipulation.

Protein analysis {#s4-3}
----------------

SDS-PAGE and quantitative immunoblotting were performed as previously described ([@bib64]). Anti-Ssa1/2 rabbit serum was provided by E. Craig (U Wisconsin---Madison), and anti-Sis1 rabbit serum was provided by M. Tuite (U Kent, Canterbury, UK). Semi-native agarose gel electrophoresis (SDD-AGE) was performed as previously described ([@bib45]). The cycloheximide SDS-sensitivity assay was performed as previously described ([@bib15]) with the following modifications: 1) cultures were treated at the various experimental temperatures for 30 min prior to the addition of cycloheximide to allow for the induction of chaperone proteins, and 2) after cycloheximide treatment, cultures were incubated with shaking at 30°C for 2 hr before lysis and analysis. For the aggregation analysis, native lysates were prepared as described previously ([@bib45]). Lysates were pre-cleared for 1 min at 500×*g* and total protein content was quantified using the BioRad Bradford assay in triplicate. Lysates were subjected to 15,000×g centrifugation for 15 min, and pellets were washed with 10 mM sodium phosphate buffer (pH7.5) containing 2% NP-40 before being resuspended in 10 mM sodium phosphate buffer (pH7.5) and quantified again in triplicate using the Bradford assay. For the Hsp104 immunocapture, native lysates were prepared at 4°C in IP buffer (50 mM HEPES--NaOH (pH 7.5), 150 mM NaCl, 10 mM MgCl~2~, 1 mM EDTA, 1% NP-40, 0.25% Na-deoxycholate, and protease inhibitors (2 mM PMSF, 5 µg/ml pepstatin, complete protease inhibitor tablets (Pierce, Rockford, IL), protease inhibitor cocktail (Sigma-Aldrich, St. Louis, MO)). Lysates were pre-cleared for 1 min at 500×*g*, and then incubated for 1 hr with Protein G magnetic beads (NEB, Ipswich, MA) with nutation. Immunocapture was performed using Protein G magnetic beads and anti-GFP mouse monoclonal antibody (Roche, Switzerland). Beads were washed 4× with IP buffer and 1× with 50 mM HEPES--NaOH (pH 7.5), and protein was eluted by boiling in SDS sample buffer. Co-captured proteins were resolved by SDS-PAGE and analyzed by gel staining with Flamingo (Bio-Rad, Hercules, CA) and fluorescent scanning on a Typhoon imager (GE Lifesciences, Marlborough, MA) according to the manufacturer\'s instructions or by western blot for GFP.

Imaging and microfluidics {#s4-4}
-------------------------

Static images were obtained on a Zeiss Axio Imager M2 fluorescence light microscope equipped with a 100× objective. Confocal images were obtained on a Zeiss LSM 510 Meta confocal microscope using a 100× objective. Microfluidics experiments were performed on a Zeiss Axio Observer Z1 using a CellAsics microfluidics plate with temperature controls and media flow of 2 psi on a Y0C4 yeast perfusion plate (channel size 3.5--5 μm). Imaging was performed in complete minimal medium supplemented with 2% glucose and 2.5 mM adenine. Fluorescence intensity was analyzed using the Zen software package (Zeiss, Germany).

Flow Cytometry {#s4-5}
--------------

Flow cytometry and cell sorting was performed on a BD FACSAria fluorescence-activated cell sorter using a 488 nm laser and a FITC-A filter to measure GFP fluorescence intensity in single cells. Data were obtained at least in triplicate with representative spectra shown. Data were analyzed using the FlowJo software package (TreeStar Inc., Ashland, OR).
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Thank you for sending your work entitled "Spatial Quality Control Bypasses Cell-Based Limitations on Proteostasis To Promote Prion Curing" for consideration at *eLife.* Your article has been favorably evaluated by Randy Schekman (Senior editor), Jeffery W Kelly (Reviewing editor), and 3 reviewers.

The Reviewing editor and the reviewers discussed their comments before we reached this decision, and the Reviewing editor has assembled the following comments to help you prepare a revised submission.

Serio and co-workers have submitted a well written and reasonably convincing manuscript demonstrating that spatial temporal retention of Hsp104 by \[*PSI*^*+*^\]^Weak^ cells induces curing through the disassembly of existing Sup35 amyloid by Hsp104. Serio et al. showed that Hsp104 must engage heat-induced protein aggregates for a period that exceeds the time to the next cell division. As a result, Hsp104 is asymmetrically localized to the cells that experienced the thermal stress ([Figures 4, 7](#fig4 fig7){ref-type="fig"}), and this increase in chaperone accumulation promotes \[*PSI*^*+*^\]^Weak^ curing in the same cells ([Figures 4, 7](#fig4 fig7){ref-type="fig"}). This study provides evidence that the engagement of Hsp104 with heat-induced misfolded Sup35 aggregates enhances proteostasis capacity by increasing the accumulation of this factor, perhaps beyond the level attainable by changes in gene expression ([Figure 4](#fig4){ref-type="fig"}), thereby enabling the disassembly of existing Sup35 amyloid ([Figure 1, 4](#fig1 fig4){ref-type="fig"}), restoring homeostasis to the mother cell. While the spatial engagement of proteostasis network components is not new, there are enough novel attributes to this work to render it an interesting *eLife* paper.

Please carefully consider the three thoughtful reviews pasted below when revising your manuscript. The points common to at least two reviews include:

1\) It is important for the model presented in this work that Hsp104 interacts specifically with aggregated proteins, and that this interaction is dependent on the enzymatic activity of Hsp104. Is it possible to demonstrate this specific interaction, e.g. by co-immunoprecipitation? How does the sequestration of Hsp104 by heat-induced aggregates affect its activity? Is it solely the consequence of achieving high local concentrations?

2\) A broader context here would be useful as a number of laboratories have made observations on Q-bodies ([@bib22]), iPOD, JUNQ ([@bib37]), aggresomes ([@bib34]), and spatial sequestration and symmetrical inheritance in yeast ([@bib76]) have demonstrated that aggregates have spatial restrictions and numerous papers have shown that multiple chaperones are associated with these aggregate structures using a wide range of proteomic and co-localization methods, often with substantial consequences on cellular activity. Some of these would seem to have opposing outcomes, which then poses questions how the mother-daughter cell relationship of yeast relates to metazoan cell division, and broader relevance to neurons being post-mitotic. Integrating these observations into this work without dramatically expanding the Discussion would be useful.

3\) The use of Sup35 as a client and the yeast cellular environment while highly relevant on its own, may not offer broadly relevant concepts than can be extrapolated to metazoans. For example, Hsp104 as a disaggregase activity is restricted to prokaryotes, plants, and yeast whereas a corresponding class of activity in metazoans appears to be a reconfiguration of the Hsp70 and J-domain apparatus by Hsp110, leading to questions whether these concepts on Hsp104 are specific to yeast (which is still interesting) or can help us to understand the larger questions posed by the authors on the upper limit of the cellular environment. Some brief comments addressing this issue will allow the reader to comprehend the bigger picture.

*Reviewer \#1*:

Protein aggregation is linked to many degenerative diseases, either through loss of function of the aggregated protein, or through a novel gain of toxic function of the aggregate. It is therefore of high importance to identify pathways that can prevent or reverse protein aggregation. The submitted manuscript investigates the relationship between protein aggregation and the aggregate-remodeling factor Hsp104.

The authors report the seemingly paradoxical observation that incubation of cells at an elevated temperature of 40^°^C strongly reduces aggregation of the model substrate Sup35 in its prion form \[*PSI*^*+*^\]^Weak^. Heat shock treatment reduces the size of the aggregates and increases the amount of soluble Sup35 after a recovery period. This process is dependent on the activity of Hsp104. The authors convincingly demonstrate that heat-induced aggregates of proteins other than Sup35 asymmetrically retain Hsp104 during cell division, in a process that is dependent of the enzymatic activity of Hsp104, and thereby increase Hsp104 concentration in mother cells to a level that allows Sup35 disaggregation and prion curing during recovery from heat stress.

The concept that the (temporary) sequestration of important proteostasis factors into an aggregate can be beneficial instead of detrimental is novel and exciting, and provides insight into an unanticipated role of asymmetric cell division in protein aggregate management. The paper is clearly written and the main conclusions are generally well supported by data.

There are however a few points the authors should address:

1\) It is important for the model presented in this work that Hsp104 interacts specifically with aggregated proteins, and that this interaction is dependent on the enzymatic activity of Hsp104. Is it possible to demonstrate this specific interaction, e.g. by co-immunoprecipitation?

2\) The use of nocodazole in [Figure 5](#fig5){ref-type="fig"} seems problematic as it may influence several other pathways that are involved in the formation and degradation of aggregates. Since the cell cycle analysis is not contributing critically to the overall model, it might be better to remove this section, or move it to the supplement.

3\) Some of the colors in [Figure 4](#fig4){ref-type="fig"} are hard to distinguish (especially dark blue and black in 4d) and are not explained in the panels.

*Reviewer \#2*:

Klaips et. al. (Serio) have explored the mechanism of curing of Sup35 prion aggregates upon exposure of yeast to transient thermal stress to test a hypothesis that the cellular environment sets limits on protein quality control (PQC). The authors show that exposure of yeast (S. cerevisiae) at specific stages of the cell cycle to short periods of thermal stress leads to the disassembly of Sup35 amyloid, and propose that this is due to the spatial sequestration of Hsp104 in the mother cell rather than the result of overall elevated levels of Hsp104 or other chaperones. The sequestration of Hsp104 is correlated with the accumulation of heat-induced, non-prion aggregates upon thermal stress and the data suggest that the disassembly of Sup35 is more a function of amplification efficiency than thermodynamic stability. FACS experiments coupled with the use of two different cell-cycle inhibitors demonstrated that prion curing was highly dependent upon the cell-cycle stage.

Overall, the experiments are well done, the results are intriguing and the paper is nicely presented. Some of the conclusions are correlative rather than causal, thus limiting the overall enthusiasm. Also, the use of Sup35 as a probe and the yeast cellular environment while highly relevant on its own, may not offer broadly relevant concepts than can be extrapolated to metazoans. For example, Hsp104 as a disaggregase activity is restricted to prokaryotes, plants, and yeast whereas a corresponding class of activity in metazoans appears to be a reconfiguration of the Hsp70 and J-domain apparatus by Hsp110, leading to questions whether these concepts on Hsp104 are specific to yeast (which is still interesting) or can help us to understand the larger questions posed by the authors on the upper limit of the cellular environment. How does the sequestration of Hsp104 by heat-induced aggregates affect its activity? Is it solely the consequence of achieving high local concentrations? An argument is made that it is the asymmetrical partitioning of Hsp104 by its association with thermal aggregates that leads to a sufficiently high concentration of Hsp104 to resolve Sup35 amyloids. What is this concentration, what is the nature and basis of the interaction? Will elevated levels of Hsp104 achieved using conditional systems or shield-based metastable DHFR achieve the same outcome? Finally, the effects of different temperature conditions are intriguing. What is the nature of the biophysical transformation of Sup35 in 30C cells compared to those exposed to 40C beyond that rather vague terminology of shift from SDS-resistant to SDS-sensitive? What is special about 40C? Is this a useful tool to understand more completely the cellular environment?

A broader context here would be useful as a number of laboratories have made observations on Q-bodies ([@bib22]), iPOD, JUNQ ([@bib37]), aggresomes ([@bib34]), and spatial sequestration and symmetrical inheritance in yeast ([@bib76]) have demonstrated that aggregates have spatial restrictions and numerous papers have shown that multiple chaperones are associated with these aggregate structures using a wide range of proteomic and co-localization methods, often with substantial consequences on cellular activity. Some of these would seem to have opposing outcomes, which then poses questions how the mother-daughter cell relationship of yeast relates to metazoan cell division, and broader relevance to neurons being post-mitotic.

Additional comments:

1\) Evidence for involvement of Hsp104 in Sup35 amyloid disassembly comes both from the literature and new data presented here, that (i) the GdnHCl curing of \[*PSI*^*+*^\]^Weak^ and a ∼50% decrease in curing efficiency was observed in a heterozygous deletion of Hsp104 ([Figure 2a, b](#fig2){ref-type="fig"}), (ii) Hsp104 was asymmetric localized upon thermal stress ([Figure 4, 6](#fig4 fig6){ref-type="fig"}) and (iii) no significant changes were observed for Hsp104, Ssa1 and Sis1 chaperone expression levels upon heat stress ([Figure 3](#fig3){ref-type="fig"}). This establishes necessity, but not sufficiency and therefore does not rule out other \'factor(s)\' induced upon heat stress that could contribute to amyloid disassembly.

These arguments can be strengthened by: (a) demonstrating whether the expression of other chaperone candidates (ie., other Hsp70 and Hsp40 isoforms) are affected by these thermal stress conditions. For example, there could be small changes in the expression of a number of chaperones that affects the cellular environment and enables amyloid resolubilization. Examples of candidates to test include chaperones examined in studies by [@bib7]; [@bib75]; [@bib17] and [@bib94], and (b) showing the over-expression data, currently not shown (p.18) that establishes that the o/e of Hsp104 alone, to the same level achieved in this study through its asymmetric retention, suffices to induce curing.

2\) The authors\' evidence for the formation of heat-induced, non-prion aggregates that accumulate upon heat stress and sequester Hsp104 in the mother cell rests on SDD-AGE ([Figure 1c](#fig1){ref-type="fig"}), differential centrifugation ([Figure 3b](#fig3){ref-type="fig"}) and that formation of aggregates correlates with other Hsp104 specific observations.

The protocol used for differential centrifugation is not sufficiently well described. It appears that the aggregates were quantified using a Bradford assay after pelleting in a tabletop centrifuge and a mild detergent wash. If the aggregates were not denatured before quantification, the presence of large particles may cause artifacts while making colorimetric measurements in a spectrophotometer. Since the quantification of these aggregates is an important aspect of this story, the authors should quantify aggregate formation with more vigor, using alternative procedures such as sucrose-density gradients and ultra-centrifugation to separate aggregates from other cellular debris. More central, the differential accumulation of aggregates in mother vs. daughter cells should be quantified and compared to the values on the differential retention of Hsp104.

3\) An important conclusion is that the heat-induced aggregates directly retain Hsp104, but there is no evidence for the direct interaction between these two factors, other than strong correlation. This would be greatly strengthened by an experiment that isolates these aggregates (see point 2 above) and demonstrates the presence of Hsp104 bound to these aggregates, using a digest and mass spectrometric quantification, for example. Alternatively, the authors could perform a co-IP experiment if they had more information on one of the proteins that is a constituent of these heat-induced aggregates.

4\) Have the authors ruled out an effect on protein synthesis? Heat shock, in particular, is well known to inhibit protein synthesis, which could affect the flux, and shift equilibria in the proper cellular environment towards dissociation?

5\) A point is regarding the relevance of the conclusions the authors make on the existence of cell-based limitations that preclude amyloid resolubilization in vivo to disease conditions. Since it is clear from their data that the cell-cycle stage is an important determinant that affects the success of resolubilization in vivo, this would not influence our understanding of the PQC in non-dividing neuronal cells. The authors should place their results in the broader context of protein misfolding diseases in the discussion.

6\) Another point in the discussion on spatial engagement of PQC factors and effects on proteostasis capacity is a recent observation ([@bib99]) on aggregate-associated sequestration of Hsc70 leading to down regulation of clathrin-mediated endocytosis. Does this suggest that the interactions of chaperones with aggregates could have different outcomes?

Reviewer \#3:

In this study, Klaips et al. perform an elegant set of studies, which demonstrate that Hsp104 dissolves Sup35 prions that encode weak \[PSI+\] at elevated temperatures in yeast. Interestingly, this curing process depends upon an unprecedented spatiotemporal mechanism. Thus, asymmetric Hsp104 retention by heat induced, non-prion aggregates in late cell cycle-stage cells, leads to high enough Hsp104 levels to promote dissolution of Sup35 prions encoding weak \[PSI+\]. Upon recognizing this potential mechanism, the authors then cleverly tweak the system to enable curing of Sup35 prions that encode strong \[PSI+\]. Although Sup35 prion dissolution by Hsp104 is not very surprising per se, the spatiotemporal mechanism revealed by these studies is entirely novel and should interest a broad audience. Indeed, this paper will raise awareness that spatiotemporal mechanisms can have a profound impact on proteostasis and amyloid resolution. In my view, the study is high quality and is carefully conducted and controlled, and I do not have any issues with the experiments or data as presented. A limitation is that several conclusions are based upon correlative evidence, but it has already been shown in vitro that Hsp104 can rapidly dissolve Sup35 prions. My only minor objections concern several statements in the Introduction that are incorrect or misleading:

1\) \'but a direct demonstration of amyloid resolubilization in vivo has yet to be reported in any system\'. Serio and colleagues have themselves already convincingly demonstrated amyloid resolublization by Hsp104 in vivo in their 2011 NSMB paper ([@bib15]). [@bib61] also provide compelling evidence that Hsp104 promotes amyloid solubilization in vivo. Moreover, there are numerous examples of amyloid clearance in conditional animal models of neurodegenerative disease models (e.g. Yamamoto et al. Cell 2000; Lim et al., J. Neuorosci. 2011). Hence, this statement is incorrect and misleading.

2\) \'Rather, the effects of chaperone overexpression have been shown in some cases to be independent of their catalytic function ([@bib5], [@bib6], [@bib33], [@bib61])\'. This statement is a little misleading as in several cases the effect has been shown to depend on catalytic function (e.g. [@bib12] PLoS Genet.)

3\) \'Extracts from *C. elegans* and mammalian tissues and cell lines similarly promote amyloid solubilization (Cohen et al., 53 2006, Murray et al., 2010).\' This statement should also be revised since Murray et al. subsequently published (Protein Sci. 2013 Nov;22(11):1531-41.) that \'our interpretation of the kinetic fibril disaggregation assay data previously reported in Bieschke et al., Protein Sci 2009;18:2231-2241 and Murray et al., Protein Sci 2010;19:836-846 is invalid when used as evidence for a disaggregase activity.\'

10.7554/eLife.04288.021

Author response

*1) It is important for the model presented in this work that Hsp104 interacts specifically with aggregated proteins, and that this interaction is dependent on the enzymatic activity of Hsp104. Is it possible to demonstrate this specific interaction, e.g. by co-immunoprecipitation*?

We agree with the reviewers that the interaction of Hsp104 with heat-induced aggregates is an essential component of our model. To address this point, we have added two new pieces of data to the manuscript. First, we demonstrate that Hsp104 co-localizes with a model substrate (firefly luciferase-mCherry), which denatures upon thermal stress and is reactivated in an Hsp104-dependent manner ([Figure 4---figure supplement 1e](#fig4s1){ref-type="fig"}; Parsell et al. 1994). Second, we demonstrate by immunocapture of Hsp104-GFP, SDS-PAGE and general protein staining, that Hsp104-GFP associates with a larger number of proteins upon thermal stress ([Figure 4a](#fig4){ref-type="fig"}). Importantly, the number of co-captured proteins increases with the severity of the stress (i.e. 40°C \> 37°C) and decreases with GdnHCl treatment ([Figure 4a](#fig4){ref-type="fig"}), which blocks Hsp104 activity. Thus, the engagement of Hsp104-GFP with heat-induced substrates parallels the efficiency of \[*PSI*^*+*^\]^Weak^ curing, which is increased at 40°C relative to 37°C ([Figure 1a, b](#fig1){ref-type="fig"}) and is inhibited by treatment with GdnHCl ([Figure 2a](#fig2){ref-type="fig"}), providing additional support for our model of prion curing.

*How does the sequestration of Hsp104 by heat-induced aggregates affect its activity? Is it solely the consequence of achieving high local concentrations*?

Our studies together indicate that both the high local concentration of Hsp104 and its activity are required for \[*PSI*^*+*^\]^Weak^ curing. To summarize here, curing correlates only with the highest levels of Hsp104 accumulation (37°C → 40°C and 40°C; [Figure 1a, b](#fig1){ref-type="fig"} and [Figure 5a](#fig5){ref-type="fig"}) and is blocked by treatments that reduce Hsp104 asymmetric accumulation (GdnHCl treatment \[[Figure 2a, 5d](#fig2 fig5){ref-type="fig"}\] and disruption of *BNI1* \[[Figure 5b, c](#fig5){ref-type="fig"}\]). In addition to these observations, we now include an additional experiment, in which cells are treated with GdnHCl after the thermal stress ([Figure 4---figure supplement 1f, g](#fig5s1){ref-type="fig"} and [Figure 5d](#fig5){ref-type="fig"}). Under these conditions, Hsp104-GFP still localizes to heat-induced aggregates ([Figure 4---figure supplement 1f](#fig4s1){ref-type="fig"}) and is asymmetrically retained ([Figure 5d](#fig5){ref-type="fig"}), but \[*PSI*^*+*^\]^Weak^ curing is reduced ([Figure 4---figure supplement 1g](#fig4s1){ref-type="fig"}), indicating that both Hsp104-GFP localization and activity are required for curing.

Prolonged overexpression of Hsp104 from a galactose-inducible promoter alone has been previously reported to induce prion curing of both \[*PSI*^*+*^\]^Strong^ ([@bib7]) and \[*PSI*^*+*^\]^Weak^ ([@bib92]). We have also previously shown that lower-level overexpression (∼5-fold) is insufficient to cure \[*PSI*^*+*^\]^Strong^ ([@bib15]). Using short induction of a galactose-inducible Hsp104 construct that transiently raises Hsp104 accumulation to the level observed with thermal stress ([Figure 3---figure supplement 1c](#fig3s1){ref-type="fig"}), we now demonstrate that \[*PSI*^*+*^\]^Weak^ curing does occur, but at a lower frequency than with thermal stress ([Figure 1b](#fig1){ref-type="fig"} and [Figure 3---figure supplement 1d](#fig3s1){ref-type="fig"}). Studies from the Ter-Avanesyan lab revealed that Sup35 SDS-resistant aggregates isolated from a \[*PSI*^*+*^\]^Strong^ strain increase in size upon Hsp104 overexpression ([@bib45]). We have confirmed this result and further demonstrated that the same holds true for SDS-resistant aggregates isolated from a \[*PSI*^*+*^\]^Weak^ strain ([Figure 3---figure supplement 1e](#fig3s1){ref-type="fig"}). This observation is in contrast to our analysis of Sup35 SDS-resistant aggregates following thermal stress. Under thermal stress, both \[*PSI*^*+*^\]^Strong^ and \[*PSI*^*+*^\]^Weak^ aggregates decrease in size ([Figure 1c](#fig1){ref-type="fig"}), and in the latter case, are disassembled to release soluble Sup35 ([Figure 1d](#fig1){ref-type="fig"}). As we address in the Discussion, these observations together indicate that the mechanisms of curing by specific overexpression of Hsp104 and by thermal stress are distinct.

*2) A broader context here would be useful as a number of laboratories have made observations on Q-bodies (*[@bib22]*), iPOD, JUNQ (*[@bib37]*), aggresomes (*[@bib34]*), and spatial sequestration and symmetrical inheritance in yeast (*[@bib76]*) have demonstrated that aggregates have spatial restrictions and numerous papers have shown that multiple chaperones are associated with these aggregate structures using a wide range of proteomic and co-localization methods, often with substantial consequences on cellular activity. Some of these would seem to have opposing outcomes, which then poses questions how the mother-daughter cell relationship of yeast relates to metazoan cell division, and broader relevance to neurons being post-mitotic. Integrating these observations into this work without dramatically expanding the Discussion would be useful*.

We thank the reviewers for these helpful suggestions. We have reworked the Discussion to more clearly link our studies to the literature available on spatial quality control and to address the distinctions between our observations of enhanced proteostasis capacity and those in the literature demonstrating reduced proteostasis capacity. We believe that these distinct outcomes arise from imbalance between chaperones and substrates created by significant perturbations of the cellular environment beyond what can be achieved naturally.

While the limitations on proteostasis capacity imposed by chaperone partitioning are clearly not applicable to post-mitotic neurons, we believe that the issues raised by a comparison of our work with those previous studies highlight the importance of system balance, particularly the role of chaperone-substrate dynamics in determining proteostasis capacity. These latter points are likely to be independent of cell-type and are clarified in the revised Discussion.

*3) The use of Sup35 as a client and the yeast cellular environment while highly relevant on its own, may not offer broadly relevant concepts than can be extrapolated to metazoans. For example, Hsp104 as a disaggregase activity is restricted to prokaryotes, plants, and yeast whereas a corresponding class of activity in metazoans appears to be a reconfiguration of the Hsp70 and J-domain apparatus by Hsp110, leading to questions whether these concepts on Hsp104 are specific to yeast (which is still interesting) or can help us to understand the larger questions posed by the authors on the upper limit of the cellular environment. Some brief comments addressing this issue will allow the reader to comprehend the bigger picture*.

The reviewer raises an important point that we failed to address in the original submission. We have now included a paragraph on mammalian disaggregase activity in the Discussion, including the similarities and distinctions with the yeast system.

Reviewer \#1:

*1) It is important for the model presented in this work that Hsp104 interacts specifically with aggregated proteins, and that this interaction is dependent on the enzymatic activity of Hsp104*. *Is it possible to demonstrate this specific interaction, e.g. by co-immunoprecipitation?*

Please see the response to point 1 under "Response to points common to at least two reviews" above.

*2) The use of nocodazole in* [*Figure 5*](#fig5){ref-type="fig"} *seems problematic as it may influence several other pathways that are involved in the formation and degradation of aggregates. Since the cell cycle analysis is not contributing critically to the overall model, it might be better to remove this section, or move it to the supplement*.

We were also concerned about off-pathway effects of nocodazole treatment, which prompted us to assess both Hsp104 expression and localization in the presence of this treatment ([Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}), and to further test the suggestions raised by these arrest experiments using single-cell analyses in asynchronous cultures ([Figure 7b, c](#fig7){ref-type="fig"}). We found no deviations from unarrested cells in either case. We believe that the cell-cycle dependence of the curing effect ([Figure 6](#fig6){ref-type="fig"}) is an important aspect of the model because it identifies the importance of heat-induced aggregate resolution relative to cell division as a key component of \[*PSI*^*+*^\]^Weak^ curing. Both reviewer 2 and reviewer 3 concur with the importance of this point in their reviews, and we have therefore retained the figure in the main figures of the revised manuscript.

*3) Some of the colors in* [*Figure 4*](#fig4){ref-type="fig"} *are hard to distinguish (especially dark blue and black in 4d) and are not explained in the panels*.

We have changed the colors in panel [Figure 4d](#fig4){ref-type="fig"} ([Figure 5b](#fig5){ref-type="fig"} in the revised manuscript) to green to increase contrast and have updated the figure legend to reflect this change.

Reviewer \#2:

*Some of the conclusions are correlative rather than causal, thus limiting the overall enthusiasm*.

We have addressed the specific comments of this reviewer below.

*Also, the use of Sup35 as a probe and the yeast cellular environment while highly relevant on its own, may not offer broadly relevant concepts than can be extrapolated to metazoans. For example, Hsp104 as a disaggregase activity is restricted to prokaryotes, plants, and yeast whereas a corresponding class of activity in metazoans appears to be a reconfiguration of the Hsp70 and J-domain apparatus by Hsp110, leading to questions whether these concepts on Hsp104 are specific to yeast (which is still interesting) or can help us to understand the larger questions posed by the authors on the upper limit of the cellular environment*.

Please see the response to point 4 under "Response to points common to at least two reviews" above.

*How does the sequestration of Hsp104 by heat-induced aggregates affect its activity*? *Is it solely the consequence of achieving high local concentrations?*

Please see the response to point 2 under "Response to points common to at least two reviews" above.

*An argument is made that it is the asymmetrical partitioning of Hsp104 by its association with thermal aggregates that leads to a sufficiently high concentration of Hsp104 to resolve Sup35 amyloids. What is this concentration, what is the nature and basis of the interaction*?

On the basis of our microfluidic analyses, curing of \[*PSI*^*+*^\]^Weak^ occurs when Hsp104 levels are increased ∼3.5-fold by thermal stress, relative to 30°C ([Table 1](#tbl1){ref-type="table"}). The interaction of Hsp104 with heat-induced substrates, as assessed by localization ([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}) and immunocapture ([Figure 4a](#fig4){ref-type="fig"}), requires its enzymatic activity (i.e. is blocked by GdnHCl treatment). These points have been clarified in the text with the addition of new data as detailed above.

*Will elevated levels of Hsp104 achieved using conditional systems or shield-based metastable DHFR achieve the same outcome*?

Please see response to point 2 under "Response to points common to at least two reviews" above for a response to the question on specific elevation of Hsp104 levels.

For model substrates, we have not attempted this precise experiment; however, in our other recently published work ([@bib29]), we note that the appearance of misfolded proteins in a \[*PSI*^*+*^\] yeast strain disrupted for the N-terminal acetyltransferase NatA leads to a decrease in the size of SDS-resistant Sup35 aggregates, but this effect is not sufficient to induce prion curing. Under these conditions, Hsp104 expression is elevated ∼3-fold, but we see no evidence of asymmetric localization by microscopy presumably due to the continued misfolding of newly-made proteins in both mother and daughter cells. Thus, both elevation of Hsp104 and its asymmetric localization are required for \[*PSI*^*+*^\]^Weak^ curing, as noted above in point 2 under "Response to points common to at least two reviews."

*Finally, the effects of different temperature conditions are intriguing. What is the nature of the biophysical transformation of Sup35 in 30C cells compared to those exposed to 40C beyond that rather vague terminology of shift from SDS-resistant to SDS-sensitive*?

We have previously demonstrated that the prion domain Sup35 transitions from an SDS-sensitive form in its monomeric state to an SDS-resistant form in its amyloid state both *in vitro* ([@bib72]) and *in vivo* ([@bib70]). We have clarified this point in the text.

*What is special about 40C? Is this a useful tool to understand more completely the cellular environment*?

Based on our studies, 40°C-treated cells accumulate more heat-induced aggregates than cells treated at 37°C ([Figure 3b](#fig3){ref-type="fig"}). This increase in accumulation correlates with an increase in the Hsp104 interactome ([Figure 4a](#fig4){ref-type="fig"}), an increase in asymmetric localization of Hsp104 ([Figure 4b, 5a](#fig4 fig5){ref-type="fig"}) and an increase in \[*PSI*^*+*^\]^Weak^ curing ([Figure 1a, b](#fig1){ref-type="fig"}). Thus, the more severe thermal stress creates a unique proteostatic niche that allows Hsp104 to resolve amyloid *in vivo*. We have stressed these points in the revised manuscript both with the additional of new data and with modifications to the text.

*A broader context here would be useful as a number of laboratories have made observations on Q-bodies (*[@bib22]*), iPOD, JUNQ (*[@bib37]*), aggresomes (*[@bib34]*), and spatial sequestration and symmetrical inheritance in yeast (*[@bib76]*) have demonstrated that aggregates have spatial restrictions and numerous papers have shown that multiple chaperones are associated with these aggregate structures using a wide range of proteomic and co-localization methods, often with substantial consequences on cellular activity. Some of these would seem to have opposing outcomes, which then poses questions how the mother-daughter cell relationship of yeast relates to metazoan cell division, and broader relevance to neurons being post-mitotic*.

Please see the response to point 3 under "Response to points common to at least two reviews" above.

*Additional comments*:

*1) Evidence for involvement of Hsp104 in Sup35 amyloid disassembly comes both from the literature and new data presented here, that (i) the GdnHCl curing of \[PSI+\]weak and a ∼50% decrease in curing efficiency was observed in a heterozygous deletion of Hsp104 (*[*Figure 2a, b*](#fig2){ref-type="fig"}*), (ii) Hsp104 was asymmetric localized upon thermal stress (*[*Figure 4, 6*](#fig4 fig6){ref-type="fig"}*) and (iii) no significant changes were observed for Hsp104, Ssa1 and Sis1 chaperone expression levels upon heat stress (*[*Figure 3*](#fig3){ref-type="fig"}*). This establishes necessity, but not sufficiency and therefore does not rule out other \'factor(s)\' induced upon heat stress that could contribute to amyloid disassembly*.

*These arguments can be strengthened by: (a) demonstrating whether the expression of other chaperone candidates (ie., other Hsp70 and Hsp40 isoforms) are affected by these thermal stress conditions. For example, there could be small changes in the expression of a number of chaperones that affects the cellular environment and enables amyloid resolubilization. Examples of candidates to test include chaperones examined in studies by* [@bib7]*;* [@bib75]*;* [@bib17] *and* [@bib94]*, and (b) showing the over-expression data, currently not shown (p.18) that establishes that the o/e of Hsp104 alone, to the same level achieved in this study through its asymmetric retention, suffices to induce curing*.

We completely agree that our studies demonstrate necessity of Hsp104 asymmetric localization and activity for \[*PSI*^*+*^\]^Weak^ curing. We believe that establishing these points represents a significant advance in the field because up until this point, the engagement of chaperones with substrates has been correlated with reduced, not enhanced, activity. As we address in the Discussion, we believe that our system, which retains all factors within their native balance, is a major reason for this distinction.

We also agree that there are likely to be other factors that are necessary to promote Sup35 amyloid disassembly in response to thermal stress. In this manuscript, we focused the assessment of this possibility on factors that are known to be required for Hsp104-mediated fragmentation of Sup35 amyloid *in vivo* (Ssa1 and Sis1). We find no evidence for asymmetric localization of these factors ([Figure 5---figure supplement 1d, e](#fig5s1){ref-type="fig"}).

With regard to curing by overexpression of Hsp104 alone, we have previously published this result for \[*PSI*^*+*^\]^Strong^ ([@bib15]). For \[*PSI*^*+*^\]^Weak^, please see the response to point 2 under "Response to points common to at least two reviews" above.

*2) The authors\' evidence for the formation of heat-induced, non-prion aggregates that accumulate upon heat stress and sequester Hsp104 in the mother cell rests on SDD-AGE (*[*Figure 1c*](#fig1){ref-type="fig"}*), differential centrifugation (*[*Figure 3b*](#fig3){ref-type="fig"}*) and that formation of aggregates correlates with other Hsp104 specific observations*.

*The protocol used for differential centrifugation is not sufficiently well described. It appears that the aggregates were quantified using a Bradford assay after pelleting in a tabletop centrifuge and a mild detergent wash. If the aggregates were not denatured before quantification, the presence of large particles may cause artifacts while making colorimetric measurements in a spectrophotometer. Since the quantification of these aggregates is an important aspect of this story, the authors should quantify aggregate formation with more vigor, using alternative procedures such as sucrose-density gradients and ultra-centrifugation to separate aggregates from other cellular debris. More central, the differential accumulation of aggregates in mother vs. daughter cells should be quantified and compared to the values on the differential retention of Hsp104*.

We have clarified our protocol for quantifying aggregates. While we did not denature the proteins before Bradford analysis, our protocol does include a preclear step to remove cellular debris. In lieu of additional characterization of aggregates on their own, we have instead included a more rigorous assessment of the Hsp104 interactome by co-immunocapture, SDS-PAGE and general protein staining. This experiment leads to the same conclusion: Hsp104 interacts with more proteins following a 40°C thermal stress than following a 37°C thermal stress ([Figure 4a](#fig4){ref-type="fig"}).

We have not quantified the differential retention of aggregates following thermal stress because Hsp104GFP has been previously demonstrated to co-localize with model proteins (VHL, ubc9ts), which misfold upon thermal stress ([@bib37]), and with oxidatively damaged proteins, which are asymmetrically retained in mother cells ([@bib21]). However, we now show that the asymmetrically retained Hsp104GFP foci co-localize with a model substrate firefly luciferase-mCherry upon thermal stress ([Figure 4---figure supplement 1e](#fig4s1){ref-type="fig"}).

*3) An important conclusion is that the heat-induced aggregates directly retain Hsp104, but there is no evidence for the direct interaction between these two factors, other than strong correlation. This would be greatly strengthened by an experiment that isolates these aggregates (see point 2 above) and demonstrates the presence of Hsp104 bound to these aggregates, using a digest and mass spectrometric quantification, for example. Alternatively, the authors could perform a co-IP experiment if they had more information on one of the proteins that is a constituent of these heat-induced aggregates*.

Please see the response to point 1 under "Response to points common to at least two reviews" above.

*4) Have the authors ruled out an effect on protein synthesis? Heat shock, in particular, is well known to inhibit protein synthesis, which could affect the flux, and shift equilibria in the proper cellular environment towards dissociation*?

There are two pieces of evidence, included in our original submission, that argues against this possibility. First, Sup35 protein levels are unchanged by the thermal stress ([Figure 3---figure supplement 1a](#fig3s1){ref-type="fig"}), a point that we now clarify in the text. Second, treatment with cycloheximide alone does not lead to Sup35 solubilization ([Figure 1d](#fig1){ref-type="fig"}), a point that we now highlight in the text.

*5) A point is regarding the relevance of the conclusions the authors make on the existence of cell-based limitations that preclude amyloid resolubilization in vivo to disease conditions. Since it is clear from their data that the cell-cycle stage is an important determinant that affects the success of resolubilization in vivo, this would not influence our understanding of the PQC in non-dividing neuronal cells. The authors should place their results in the broader context of protein misfolding diseases in the discussion*.

Please see the response to point 3 under "Response to points common to at least two reviews" above.

*6) Another point in the discussion on spatial engagement of PQC factors and effects on proteostasis capacity is a recent observation (*[@bib99]*) on aggregate-associated sequestration of Hsc70 leading to down regulation of clathrin-mediated endocytosis. Does this suggest that the interactions of chaperones with aggregates could have different outcomes*?

The reviewer raises an interesting point. It is certainly possible that sequestration of chaperones can lead to different outcomes in different situations. Another possibility is that the outcomes are dictated by the experimental conditions. Our studies are distinct from those of Yu *et al.* in that the latter study employs aggregation-prone proteins that are expressed to high levels, which could promote imbalance in the system, as we address in the Discussion. We are in the early stages of understanding non-transcriptional mechanisms for regulating chaperone activity in cells, and these distinctions highlight interesting lines of investigation to pursue in the future.

Reviewer \#3:

*1) \'but a direct demonstration of amyloid resolubilization in vivo has yet to be reported in any system\'. Serio and colleagues have themselves already convincingly demonstrated amyloid resolublization by Hsp104 in vivo in their 2011 NSMB paper (*[@bib15]*).* [@bib61] *also provide compelling evidence that Hsp104 promotes amyloid solubilization in vivo. Moreover, there are numerous examples of amyloid clearance in conditional animal models of neurodegenerative disease models (e.g. Yamamoto et al. Cell 2000; Lim et al., J. Neuorosci. 2011). Hence, this statement is incorrect and misleading*.

We apologize for the confusion regarding this sentence. The text in question was meant to refer to studies in which chaperones were specifically overexpressed in amyloid model systems. We do agree with the reviewer that additional literature demonstrating amyloid clearance upon repression of synthesis of the amyloidogenic protein, as well as the effects of dominant-negative mutants are important to consider as well. We have re-written this part of the Introduction to highlight the facts that 1) chaperone overexpression has not been demonstrated to resolve amyloid *in vivo* and 2) amyloid clearance mechanisms must exist *in vivo*, although they are ineffective against continuously expressed, wildtype amyloid proteins.

With regard to the studies of Park *et al.* 2014, we disagree with the reviewer on the strength of the evidence supporting amyloid resolubilization *in vivo*. First, these studies are conducted under conditions of continued protein synthesis and over extended time frames, and as we have previously demonstrated (Satpute-Krishnan and Serio, 2005); newly-made protein quickly accumulates in a soluble form when Hsp104 activity is inhibited. Second, the interpretation of these microscopy experiments is inconsistent with previous biochemical studies that demonstrate an increase in the size of Sup35 aggregates upon Hsp104 overexpression, which we have reproduced for both the \[*PSI*^*+*^\]^Strong^ and \[*PSI*^*+*^\]^Weak^ variants ([Figure 3---figure supplement 1e](#fig3s1){ref-type="fig"}). We have clarified these points in the Discussion.

*2) \'Rather, the effects of chaperone overexpression have been shown in some cases to be independent of their catalytic function (*[@bib5]*,* [@bib6]*,* [@bib33]*,* [@bib61]*)\'. This statement is a little misleading as in several cases the effect has been shown to depend on catalytic function (e.g.* [@bib12] *PLoS Genet*.*)*

Again, we apologize for the confusion. Our statement was meant to only refer to the citations listed (hence the "some"), but we can see how this narrow discussion of the literature can lead to confusion. Rather than expand to include the Cushman-Nick study, which incidentally shows that overexpression of Hsp104 promotes amyloid formation by MJD rather than clearance of existing amyloid, we have deleted this sentence.

*3) \'Extracts from* C. elegans *and mammalian tissues and cell lines similarly promote amyloid solubilization (Cohen et al., 53 2006, Murray et al., 2010).\' This statement should also be revised since Murray et al. subsequently published (Protein Sci. 2013 Nov;22(11):1531-41.) that \'our interpretation of the kinetic fibril disaggregation assay data previously reported in Bieschke et al., Protein Sci 2009;18:2231-2241 and Murray et al., Protein Sci 2010;19:836-846 is invalid when used as evidence for a disaggregase activity.*\'

We thank the reviewer for pointing us to the Murray et al. 2013 manuscript. We have removed the previous references to disaggregase activity in metazoan extracts.

[^1]: These authors contributed equally to this work.

[^2]: Max Planck Institute of Biochemistry, Munich, Germany.

[^3]: Department of Molecular and Cell Biology, University of California, Berkeley, Berkeley, United States.

[^4]: \[*PSI*^+^\]^Weak^ *HSP104GFP*(SY2126), *SSA1GFP* (SY2658), or *SIS1GFP* (SY2447) cultures were treated at indicated temperatures and were imaged over time at 30°C using microfluidics and fluorescence microscopy. Average fluorescence intensity in mother cells with indicated standard deviations (±), which originated from budded cells at the time of thermal stress, was measured at the first cell division. Number of cells analyzed is indicated in parentheses. p values are \<0.001 for all comparisons to 30°C treatment.
